Satdarshan P. Singh Monga CURRICULUM VITAE …...Ko S, Russell JO, Tian J, Gao C, Kobayashi M, Feng R, Yuan X, Shao C, Ding H, Poddar M, Singh S, Locker J, Weng HL, Monga SP, Shin

Curriculum Vitae Satdarshan (Paul) Monga, MD, FAASLD Revision: Dec. 2018 1

Satdarshan P. Singh Monga

CURRICULUM VITAE University of Pittsburgh

School of Medicine

BIOGRAPHICAL Home Address: 1606 English Oak Court Birth Place: Patiala, Punjab, India

Wexford, PA 15090 Home Phone: (724) 935-4483 Citizenship: USA Office Address: S421 BST, 200 Lothrop Street Email: [email protected] Pittsburgh, PA 15261 [email protected]

Business Phone: (412) 648-9966 Fax: (412) 648-1916 Web:

http://path.upmc.edu/Exp-Pathology/dep.htm

http://path.upmc.edu/personnel/Faculty/Monga.htm

http://www.livercenter.pitt.edu/people/faculty/paul-monga-md

http://www.upci.upmc.edu/mccbp/Satdarshan-Monga.cfm?member=332

http://www.mirm.pitt.edu/people/bios/Monga1.asp

http://www.mcgowan.pitt.edu/CATER/about/about_us.asp

EDUCATION and TRAINING

UNDERGRADUATE: 1986-1988 MM Modi College, Patiala, F.Sc Biology Punjab, India GRADUATE: 1988-1992 Dayanand Medical College & M.D. Medicine Hospital, Ludhiana and Punjab (M.B.B.S) & Surgery University, Chandigarh, India 1993 DMC & H, Ludhiana, Punjab, 1993 Internship India

http://path.upmc.edu/Exp-Pathology/dep.htm

http://path.upmc.edu/personnel/Faculty/Monga.htm

http://www.livercenter.pitt.edu/people/faculty/paul-monga-md

http://www.upci.upmc.edu/mccbp/Satdarshan-Monga.cfm?member=332

http://www.mirm.pitt.edu/people/bios/Monga1.asp

http://www.mcgowan.pitt.edu/CATER/about/about_us.asp


POSTGRADUATE: 1996-1997 Georgetown University Hospital Research Gastroenterology/ & Dept of Veterans Affairs Medical Fellow Developmental Biology/

Center, Washington, D.C Molecular Biology 1997-1999 Fels Cancer Institute, Postdoctoral Gastroenterology/ Temple University Hospital, Fellow Molecular Biology/ Philadelphia PA Biochemistry

APPOINTMENTS and POSITIONS

ACADEMIC: 1999-2001 University of Pittsburgh, School of Medicine Research Associate

Department of Pathology 2001-2003 University of Pittsburgh, School of Medicine Research Assistant Division of Cellular & Molecular Pathology Professor 2001-present McGowan Institute of Regenerative Medicine Member faculty

Liver Section, University of Pittsburgh, SOM 2002-present University of Pittsburgh Cancer Institute Member faculty

Molecular and Cellular Biology Program 2002-2005 McGowan Institute of Regenerative Medicine Director Graduate Student Network (now MTCAP) 2003-2007 University of Pittsburgh, School of Medicine Assistant Professor of

Division of Cellular & Molecular Pathology Pathology 2004-2007 University of Pittsburgh, School of Medicine Assistant Professor of

Division of Gastroenterology Medicine 2005-2013 McGowan Institute of Regenerative Medicine Director

Trainee Career Advancement Program (MTCAP) 2007-2012 University of Pittsburgh, School of Medicine Associate Professor of

Division of Experimental Pathology Pathology 2007-2012 University of Pittsburgh, School of Medicine Associate Professor of

Division of Gastroenterology Medicine

2008-present University of Pittsburgh, School of Medicine Division Director Division of Experimental Pathology 2011-present Cellular Approaches to Tissue Engineering and Program Director

Regeneration Program, MIRM


2012-present University of Pittsburgh, School of Medicine Professor of

Division of Experimental Pathology Pathology 2012-present University of Pittsburgh, School of Medicine Professor of

Division of Gastroenterology, Hepatology & Medicine Nutrition

2013-present University of Pittsburgh, School of Medicine Vice-Chair of

Department of Pathology Experimental Pathology

2015-present University of Pittsburgh, School of Medicine Assistant Dean, Co-Director Department of Pathology Medical Scientist Training

Program (MSTP)

2016-present University of Pittsburgh, School of Medicine Director, Pittsburgh Department of Pathology Liver Research Center

NON-ACADEMIC: 1994-1995 Monga Nursing Home/Hospital, Bareta, Residential Medical

Punjab, India Officer

1995-1996 Dayanand Medical College & Hospital Medical Officer In-Charge Dept. of Social & Preventive Medicine, Ludhiana, Punjab, India

CERTIFICATION and LICENSURE

Medical Licensure:

Punjab Medical Council, Chandigarh, India 1992

Medical Degree: Punjab University, Chandigarh, India 1994

MEMBERSHIP in PROFESSIONAL and SCIENTIFIC SOCIETIES American Physiology Society 2016-present PLUTO (American Association of University Pathologists) 2011-present American Society for Clinical Investigations (ASCI) 2009-present American Association for The Study of Liver Diseases (AASLD) 2006-present American Society of Investigative Pathology (ASIP) 2002-present


American Association of Cancer Research (AACR) 2001-present American Gastroenterology Association (AGA) 1999-present

Society of Developmental Biology (SDB) 1997-2005

HONORS and AWARDS

Takeda Distinguished Research Award of the APS 2019

Gastrointestinal & Liver Physiology Section

Top 100 Abstracts, AASLD annual meeting, San Francisco, CA 2018 10th Annual Rao Lectureship, Northwestern University, Chicago 2018 Nominated for 2019 Takeda Distinguished Scientist Award, 2017 American Physiology Society Program Chair, American Society of Investigative Pathology standalone 2017 Meeting, PISA 2017, Pittsburgh, PA American Society of Investigative Pathology Presidential Symposia 2017 Speaker, Chicago Dr. Michael Gerber Memorial Lecture, Dept. of Pathology, 2017

Tulane University, New Orleans, LO American Association for the Study of the Liver Diseases Fellow 2016 FAASLD Secretary Treasurer, American Society of Investigative Pathology 2016 Recipient of the Robert E. Stowell Lectureship 2016 UC Davis, Department of Pathology Chair: Liver Workshop, Experimental Biology (EB) 2016

San Diego, CA

Editor-in-Chief, Gene Expression: The Journal of 2015 Basic Liver Research (Cognizant Communication) Medical Student Research Mentoring Merit Award, 2015

University of Pittsburgh, School of Medicine Chair: Liver Symposia, Experimental Biology (EB) 2015

Boston, MA Associate Editor, Journal of Hepatology 2014 Program Chair-Elect 2014


American Society of Investigative Pathology Outstanding Investigator Award, 2014

American Society of Investigative Pathology Chair: Liver Workshop, Experimental Biology (EB) 2014

San Diego, CA Chair, Basic Research Workshop on Liver Regeneration, 2013 AASLD Annual Meeting, Washington DC Moderator-Early Morning Workshop on HCC 2013

AASLD Annual Meeting, Washington DC

Inaugural Provost Lecture, University of Pittsburgh 2013 Chair: Liver Workshop and Symposia, Experimental Biology (EB), 2013

Boston, MA Endowed Chair for Experimental Pathology 2012 Editor-in-Chief: Current Pathobiology Reports, Springer Journals 2012 ASIP Program Chair- Joint ASIP and Society of Italian Pathologists 2012

Meeting, Udine, Italy

Chair: Liver Workshop and Symposia, Experimental Biology (EB), 2012 San Diego, CA

Editorial Board, Journal of Hepatology 2012 Editorial Board, Gastroenterology 2012 Visiting Professor, University of Cagliari, Sardinia, Italy 2011 Chair: Liver Symposia, EB 2011

Washington, DC Inducted into PLUTO (American Association of University Pathologists) 2011

Distinguished Mentor Merit Award, Graduate Training, IBGP 2011

University of Pittsburgh, SOM William E. Brown Outstanding Mentor Award, MSTP program 2011

University of Pittsburgh, SOM

Organizer, FASEB summer research conference on Liver Biology 2010 Chair-Special Task Force, Meetings and Courses, ASIP 2010 ASIP Program Chair- Joint ASIP and Society of Italian Pathologists 2010

Meeting, Salerno, Italy


Chair-Liver Workshop, Experimental Biology 2010

Anaheim, CA Moderator-Early Morning Workshop, Annual AASLD Meeting 2009

Boston, MA Nominated for Vice-President, ASIP 2009 Conferral of Tenure 2009 Elected to the American Society for Clinical Investigations 2009 Co-Moderator, Hepatobiliary Cancer, Translational 2008

AASLD Parallel Session XVIII Editorial Board, Hepatology 2009

Accepted to be the Editor of Book entitled ‘Molecular Pathology 2008

Of Liver Diseases’ Springer (2010) Associate Editor 2008

American Journal of Pathology Guest Editor, Journal of ORGANOGENESIS (April) 2008

Chair, Stem Cell, Focused Research Group, AASLD annual 2007

meeting, Boston

Chair, AASLD Research Forum entitled ‘Gene Expression and 2007 Cell Signaling’, Digestive Diseases Week’, Washington DC

Program Chair-Elect for the American Society of Investigative 2007

Pathology Chair, Liver Symposia at ASIP annual meeting at EB 2007 2007

‘Pathobiology of ASH and NASH’

Chair, Stem Cell Symposia at ASIP annual meeting 2007 Experimental Biology 2007

Senior Vice Chancellor Award, University of Pittsburgh, SOM 2006 Invited presenter at Harry and Elsa Jiler- 2005

American Cancer Society Professors Meeting Invited speaker at the Annual Science 2005 meeting at the University 2005

of Pittsburgh, SOM Chair, Liver Workshop, ASIP annual meeting, 2005

EB 2005, San Francisco


Chair, Neoplasia Symposium, ASIP annual meeting, 2005

EB 2005, San Francisco

Vice Chair, Stem cells Poster discussion session, ASIP annual meeting 2004 EB 2004 Annual Conference

American Cancer Society, Research Scholar Award (Rank-1/43) 2003 Plenary Poster of Distinction at the annual American Gastroenterology 2003

Association meeting, Digestive Diseases Week (DDW)-2003 Chairperson and Guest of Honor at the 35th Annual Conference 2002

of Indian Pharmacological Society (26-29 November, 2002)

President Plenary Abstract Presentation, Advances in GI Oncology 2002 at the AGA meeting, DDW-2002

Pathology Postdoctoral Research Training Award 2000

President Plenary Abstract Presentation at the annual AGA meeting, 1999

DDW-1999 Plenary Poster of Distinction at the AGA meeting, DDW-1999 1999 Nominated for AASLD ‘Fellow of the Year’ Award 1998

PUBLICATIONS

Refereed articles

1. Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh, Poddar M, Monga JS, Liu P, Oertel M, Ranganathan S, Singhi A, Rebouissou S, Zucman-Rossi J, Ribback S, Calvisi D, Qvartskhava N, Görg B, Häussinger D, Chen X, Monga SP. Wnt-β-catenin-GS-glutamine-mTORC1 axis in metabolic zonation and β-catenin-mutated liver tumors offers novel therapeutic opportunities. Cell Metabolism (In Press).

2. Jiang A, Okabe H, Popovic B, Preziosi ME, Pradhan-Sundd T, Poddar M, Singh S, Bell A, England S, Nagarajan S, Monga SP. Loss of Wnt secretion by macrophages promotes hepatobiliary injury following administration of DDC diet. American Journal of Pathology (In Press).

3. Qiao Y, Xu M, Tao J, Che L, Cigliano A, Monga SP, Calvisi DF, Chen X. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice. BMC Cancer. 2018 Nov 12;18(1):1093. doi: 10.1186/s12885-018-4870-z. PubMed PMID: 30419856; PubMed Central PMCID:PMC6233269.


4. Saggi H, Maitra D, Jiang A, Zhang R, Wang P, Cornuet P, Singh S, Locker J, Ma X, Dailey H, Abrams M, Omary MB, Monga SP, Nejak-Bowen K. Loss of hepatocyte β-Catenin protects mice from experimental porphyria-associated liver injury. J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32442-5. doi: 10.1016/j.jhep.2018.09.023. [Epub ahead of print] PubMed PMID: 30287339.

5. Ko S, Russell JO, Tian J, Gao C, Kobayashi M, Feng R, Yuan X, Shao C, Ding H, Poddar M, Singh S, Locker J, Weng HL, Monga SP, Shin D. Hdac1 Regulates Differentiation of Bipotent Liver Progenitor Cells During Regeneration via Sox9b and Cdk8. Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35033-9. doi:10.1053/j.gastro.2018.09.039. [Epub ahead of print] PubMed PMID: 30267710.

6. Zhang R, Kikuchi AT, Nakao T, Russell JO, Preziosi ME, Poddar M, Singh S, Bell AW, England SG, Monga SP. Elimination of Wnt secretion from stellate cells is dispensable for zonation and development of liver fibrosis following hepatobiliary injury. Gene Expr. 2018 Sep 20. doi:10.3727/105221618X15373858350141. [Epub ahead of print] PubMed PMID: 30236172.

7. Russell JO, Lu WY, Okabe H, Abrams M, Oertel M, Poddar M, Singh S, Forbes SJ, Monga SP. Hepatocyte-specific β-catenin deletion during severe liver injury provokes cholangiocytes to differentiate into hepatocytes. Hepatology. 2018 Sep 14. doi: 10.1002/hep.30270. [Epub ahead of print] PubMed PMID: 30215850. Accompanying Editorial

8. Mattu S, Saliba C, Sulas P, Zavattari P, Perra A, Kowalik MA, Monga SP, Columbano A. High Frequency of β-Catenin Mutations in Mouse Hepatocellular Carcinomas Induced by a Nongenotoxic Constitutive Androstane Receptor Agonist. Am J Pathol. 2018 Sep 8. pii: S0002-9440(17)31145-8. doi:10.1016/j.ajpath.2018.07.022. [Epub ahead of print] PubMed PMID: 30201494.

9. Preziosi M, Okabe H, Poddar M, Singh S, Monga SP. Endothelial Wnts regulate β-catenin signaling in murine liver zonation and regeneration: A sequel to the Wnt-Wnt situation. Hepatol Commun. 2018 Jun 21;2(7):845-860. doi: 10.1002/hep4.1196. eCollection 2018 Jul. PubMed PMID: 30027142; PubMed Central PMCID: PMC6049069.

10. Pradhan-Sundd T, Vats R, Russell JM, Singh S, Michael AA, Molina L, Kakar S, Cornuet P, Poddar M, Watkins SC, Nejak-Bowen KN, Monga SP, Sundd P. Dysregulated bile transporters and impaired tight junctions during chronic liver injury in mice. Gastroenterology. 2018 Jun 28. pii: S0016-5085(18)34690-0. doi:10.1053/j.gastro.2018.06.048. PubMed PMID: 29964040.

11. Molina L, Bell D, Tao J, Preziosi M, Pradhan-Sundd T, Singh S, Poddar M, Luo J,

Ranganathan S, Chikina M, Monga SP. Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma. Am J Pathol. 2018 Jun 18. pii: S0002-9440(17)31236-1. doi: 10.1016/j.ajpath.2018.05.006. [Epub ahead of print] PubMed PMID: 29920228.


12. Jaiswal G, Singh G, Dar MS, Singh P, Bano N, Syed SH, Sandhu P, Akhter Y, Monga SP, Dar MJ. Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/β-catenin signaling pathways. Biochim Biophys Acta. 2018 Jun;1865(6):920-931. doi: 10.1016/j.bbamcr.2018.03.013. Epub 2018 Apr PubMed PMID: 29621572.

13. Russell JO, Ko S, Saggi HS, Singh S, Poddar M, Shin D, Monga SP. Bromodomain and

Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration. Am J Pathol. 2018 Mar 12. pii: S0002-9440(17)30773-3. doi: 10.1016/j.ajpath.2018.02.006. [Epub ahead of print] PubMed PMID: 29545201.

14. Preziosi M, Poddar M, Singh S, Monga SP. Hepatocyte Wnts are dispensable during diethylnitrosamine and carbon tetrachloride-induced injury and hepatocellular cancer. Gene Expr. 2018 Mar 8. doi: 10.3727/105221618X15205148413587. [Epub ahead of print] PubMed PMID: 29519268.

15. Zhan N, Adebayo Michael A, Wu K, Zeng G, Bell A, Tao J, Monga SP. The effect of selective

c-met inhibitor on HCC in the Met-active, β-catenin mutated mouse model. Gene Expr. 2018 Feb 6. doi: 10.3727/105221618X15174108894682. [Epub ahead of print] PubMed PMID: 29409568.

16. Pradhan-Sundd T, Zhou L, Vats R, Jiang A, Molina L, Singh S, Poddar M, Russell JM, Stolz

DB, Oertel M, Apte U, Watkins S, Ranganathan S, Nejak-Bowen KN, Sundd P, Monga SP. Dual catenin loss in murine liver causes tight junctional deregulation and progressive intrahepatic cholestasis. Hepatology. 2017 Oct 10. doi: 10.1002/hep.29585. PubMed PMID: 29023813. Accompanying Editorial

17. Liu C, Ren YF, Dong J, Ke MY, Ma F, Monga SP, Wu R, Lv Y, Zhang XF. Activation of SRY

accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma. Cancer Lett. 2017 Dec 1;410:20-31. doi: 10.1016/j.canlet.2017.09.013. Epub 2017 Sep 21. PubMed PMID: 28942012.

18. Puliga E, Min Q, Tao J, Zhang R, Pradhan-Sundd T, Poddar M, Singh S, Columbano A, Yu J,

Monga SP. Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer. Am J Pathol. 2017 Nov;187(11):2473-2485. doi: 10.1016/j.ajpath.2017.07.005. Epub 2017 Aug 12. PubMed PMID: 28807594.

19. Kikuchi A, Pradhan-Sundd T, Singh S, Nagarajan S, Loizos N, Monga SP. Platelet-Derived

Growth Factor Receptor α Contributes to Human Hepatic Stellate Cell Proliferation and Migration. Am J Pathol. 2017 Oct;187(10):2273-2287. doi: 10.1016/j.ajpath.2017.06.009. Epub 2017 Jul 20. PubMed PMID: 28734947. (Recommended by F1000)

20. Thompson MD, Moghe A, Cornuet P, Marino R, Tian J, Wang P, Ma X, Abrams M, Locker J,

Monga SP, Nejak-Bowen K. β-catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis. Hepatology. 2017 Jul 17. doi: 10.1002/hep.29371. [Epub ahead of print]. PMID:28714273. Accompanying Editorial

21. Nejak-Bowen K, Moghe A, Cornuet P, Preziosi M, Nagarajan S, Monga SP. Role and

regulation of p65/β-catenin association during liver injury and regeneration: a 'complex' relationship. Gene Expr. 2017 Apr 28.


22. Chen ZH, Yu YP, Zuo ZH, Nelson JB, Michalopoulos GK, Monga SP, Liu S, Tseng G, Luo JH. Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene. Nat Biotechnol. 2017 May 1. doi: 10.1038/nbt.3843.

23. Preziosi ME, Singh S, Valore EV, Jung G, Popovic B, Poddar M, Nagarajan S, Ganz T,

Monga SP. Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload. J Hepatol. 2017 Mar 22. pii: S0168-8278(17)30146-0. doi: 10.1016/j.jhep.2017.03.012.

24. Chen ZH, Yu YP, Tao J, Liu S, Tseng G, Nalesnik M, Hamilton R, Bhargava R, Nelson JB,

Pennathur A, Monga SP, Luketich JD, Michalopoulos GK, Luo JH. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice. Gastroenterology. 2017 Feb 25. pii: S0016-5085(17)30004-5. doi: 10.1053/j.gastro.2016.12.036.

25. Tao J, Zhang R, Singh S, Poddar M, Xu E, Oertel M, Chen X, Ganesh S, Abrams M, Monga

SP. Targeting β-catenin in hepatocellular cancers induced by co-expression of mutant β-catenin and K-Ras in mice. Hepatology. 2016 Dec 16. doi: 10.1002/hep.28975. PMID: 27981621. Accompanying Editorial

26. Okabe Yang J, Sylakowski K, Yovchev M, Miyagawa Y, Nagarajan S, Chikina M, Thompson M, Oertel M, Baba H, Monga SP, Nejak-Bowen KN. Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice. Hepatology. 2016 Nov. 64 (5): 1652-1666. PubMed PMID: 27533619. PubMed Central PMCID: PMC5074849

27. Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, Monga

SP. Modeling a human HCC subset in mice through co-expression of Met and mutant β-catenin. Hepatology 2016 Nov. 64 (5): 1587-1605. PubMed PMID: 27097116; PubMed Central PMCID: PMC5073058 Accompanying Editorial

28. Wang H, Lu J, Edmunds LR, Kulkarni S, Dolezal J, Tao J, Ranganathan S, Jackson L,

Fromherz M, Beer-Stolz D, Uppala R, Bharathi S, Monga SP, Goetzman ES, Prochownik EV. Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma. J Biol Chem. 2016 Dec 16;291(51):26241-26251. PubMed PMID:27738108.

29. Ganesh S, Koser M, Cyr W, Chopda G, Tao J, Shui X, Ying B, Chen D, Pandya P,

Chipumuro E, Siddiquee Z, Craig K, Lai C, Dudek H, Monga SP, Wang W, Brown BD, Abrams M. Direct pharmacological inhibition of β-catenin by RNA interference in tumors of diverse origin. Mol Cancer Ther. 2016 Jul 7.

30. Dar MS, Singh P, Singh G, Jamwal G, Hussain SS, Rana A, Akhter Y, Monga SP, Dar MJ.

Terminal regions of β-catenin are critical for regulating its adhesion and transcription functions. Biochim Biophys Acta. 2016 Sep;1863(9):2345-57. doi: 10.1016/j.bbamcr.2016.06.010. Epub 2016 Jun 29.

31. Alvarado TF, Puliga E, Preziosi M, Poddar M, Singh S, Columbano A, Nejak-Bowen K, Monga SP. Thyroid Hormone Receptor-β Agonist Induces β-Catenin-Dependent Hepatocyte Proliferation in Mice: Implications in Hepatic Regeneration. Gene Expr. 2016 May 24.


32. Edmunds LR, Otero PA, Sharma L, D'Souza S, Dolezal JM, David S, Lu J, Lamm L, Basantani M, Zhang P, Sipula IJ, Li L, Zeng X, Ding Y, Ding F, Beck ME, Vockley J, Monga SP, Kershaw EE, O'Doherty RM, Kratz LE, Yates NA, Goetzman EP, Scott D, Duncan AW, Prochownik EV. Abnormal lipid processing but normal long-term repopulation potential of myc-/- hepatocytes. Oncotarget. 2016 Apr 20.

33. Okabe H, Kinoshita H, Imai K, Nakagawa S, Higashi T, Arima K, Uchiyama H, Ikegami T, Harimoto N, Itoh S, Ishiko T, Yoshizumi T, Beppu T, Monga SP, Baba H, Maehara Y. Diverse Basis of β-Catenin Activation in Human Hepatocellular Carcinoma: Implications in Biology and Prognosis. PLoS One. 2016 Apr 21;11(4):e0152695.

34. Cordi S, Godard C, Saandi T, Jacquemin P, Monga SP, Colnot S, Lemaigre FP. Role of β-

catenin in development of bile ducts. Differentiation. 2016 Feb 5. pii: S0301-4681(15)30040-2. doi: 10.1016/j.diff.2016.02.001.

35. Jiansheng Huang, Andrew E. Schriefer, Paul F. Cliften, Dennis Dietzen, Sakil Kulkarni, Sucha Singh, Monga SP, David A. RudnickP ostponing the H ypoglycem ic R esponse to Partial Hepatectomy Delays Mouse Liver Regeneration. Am J Pathol. 2016 Mar;186(3):587-99. doi:10.1016/j.ajpath.2015.10.027.

36. Al-Bataineh MM, Kinlough CL, Poland PA, Pastor-Soler NM, Sutton TA, Mang HE, Bastacky SI, Gendler SJ, Madsen CS, Singh S, Monga SP, Hughey RP. Muc1 enhances the β-catenin protective pathway during ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2016 Mar 15;310(6):F569-79. doi: 10.1152/ajprenal.00520.2015.

37. Ko S, Choi TY, Russell JO, So J, Monga SP, Shin D. Bromodomain and extraterminal (BET) proteins regulate biliary-driven liver regeneration. J Hepatol. 2015 Oct 23. pii: S0168-8278(15)00716-3. doi: 10.1016/j.jhep.2015.10.017. J Hepatol. 2016 Feb;64(2):316-25. doi: 10.1016/j.jhep.2015.10.017. PubMed PMID: 26505118; PubMed Central PMCID: PMC4718879.

38. Lili Zhou, Tirthadipa Pradhan-Sundd, Minakshi Poddar, Sucha Singh, Alex Kikuchi, Donna Beer Stolz, Weinian Shou, Zongfang Li, Kari Nichole Nejak-Bowen, Monga SP. Mice with hepatic loss of the desmosomal protein γ-catenin are prone to cholestatic injury and chemical carcinogenesis. Am J Pathol. 2015 Dec;185(12):3274-89. doi: 10.1016/j.ajpath.2015.08.019.

39. Eisses JF, Criscimanna A, Dionise ZR, Orabi AI, Javed TA, Sarwar S, Jin S, Zhou L, Singh S, Poddar M, Davis AW, Tosun AB, Ozolek JA, Lowe ME, Monga SP, Rohde GK, Esni F, Husain SZ. Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs. Am J Pathol. 2015 Oct 23. pii: S0002-9440(15)00494-0. doi: 10.1016/j.ajpath.2015.08.006.

40. Guoliang Wang, Hui Wang, Sucha Singh, Pei Zhou, Shengyong Yang, Yujuan Wang Zhaowei Zhu, Jinxiang Zhang, Alex Chen, Timothy Billiar, Monga SP, Qingde Wang. Adar1 prevents liver injury from inflammation and suppresses interferon production in hepatocytes. Accepted. Am J Pathol. 2015 Dec;185(12):3224-37. doi: 10.1016/j.ajpath.2015.08.002.

41. Jing Yang, Antonella Cussimano, Jappmann Monga, Morgan Preziosi, Filippo Pullara, Guillerma Calero, Richard Lang, Terry Yamaguchi, Kari Nichole Nejak-Bowen, Monga SP. Wnt5a inhibits hepatocyte proliferation and concludes β-catenin signaling in liver regeneration. American Journal of Pathology. Am J Pathol. 2015 Aug;185(8):2194-205.


42. Pastor-Soler NM, Sutton TA, Mang HE, Kinlough CL, Gendler SJ, Madsen CS, Bastacky SI, Ho J, Al-Bataineh MM, Hallows KR, Singh S, Monga SP, Kobayashi H, Haase VH, Hughey RP. Muc1 is Protective during Kidney Ischemia-Reperfusion Injury. Am J Physiol Renal Physiol. 2015 Apr 29:ajprenal.00066.2015.

43. Delgado A, Okabe H, Preziosi M, Russell JO, Alvarado TF, Oertel M, Nejak-Bowen KN, Zhang Y, Monga SP. Complete response of Ctnnb1-mutated tumors to β-catenin suppression by locked nucleic antisense in mouse hepatocarcinogenesis model. Journal of Hepatology. J Hepatol. 2015 Feb;62(2):380-7. Accompanying Editorial.

44. Bhushan B, Walesky C, Manley M, Gallagher T, Borude P, Edwards G, Monga SP, Apte U. Pro-Regenerative Signaling after Acetaminophen-Induced Acute Liver Injury in Mice Identified Using a Novel Incremental Dose Model. Am J Pathol. 2014 Sep 2. pii: S0002-9440(14)00437-4. doi: 10.1016/j.ajpath.2014.07.019.

45. Hirohisa Okabe, Evan Delgado, Jung Min Lee, Jing Yang, Hiroki Kinoshita, Hiromitsu Hayashi, Allan Tsung, Jaideep Behari, Toru Beppu, Hideo Baba, Monga SP. Monga. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma. PLOS ONE 2014 Jun 3;9(6):e98817.

46. Junyan Tao, Diego F. Calvisi, Sarangarajan Ranganathan, Antonio Cigliano, Lili Zhou, Sucha Singh, Lijie Jiang, Biao Fan, Luigi Terracciano, Sorin Armeanu-Ebinger, Silvia Ribback, Frank Dombrowski, Matthias Evert, Xin Chen, Monga SP. Wnt/β-catenin and Yap pathways synergize to promote hepatoblastoma development in mice and men. Gastroenterology, 2014 May 14. pii: S0016-5085(14)00610-6. doi: 10.1053/. Accompanying Editorial.

47. Evan Delgado, Jing Yang, Juhoon So, Stephanie Leimgruber, Michael Kahn, Tohru Ishitani, Donghun Shin, Gabriela Mustata Wilson, Monga SP. Identification and characterization of a novel small molecule inhibitor of beta-catenin signaling. Am J Pathol. 2014 Jul;184(7):2111-22.

48. Jing Yang, Laura E. Mowry, Kari Nichole Nejak-Bowen, Hirohisa Okabe, Cassandra R.

Diegel, Richard Lang, Bart Williams, Monga SP. Beta-catenin signaling in murine liver zonation and regeneration: A Wnt-Wnt situation. Hepatology 2014 Feb 20.

49. Fanti M, Singh S, Ledda-Columbano GM, Columbano M, Monga SP. Triiodothyronine

induces hepatocyte proliferation by protein kinase A-dependent β-catenin activation in rodents. Hepatology. 2014 Jun;59(6):2309-20. Accompanying Editorial.

50. Lee JM, Yang J, Newell PN, Singh S, Parwani A, Friedman SL, Nejak-Bowen KN, Monga

SP. Beta-catenin signaling in hepatocellular cancer. Implications in inflammation, fibrosis and proliferation. Cancer Letters, 2013, Sep. 23.

51. Delgado E, Bahal R, Yang J, Lee JM, Ly DH, Monga SP. β-Catenin Knockdown in Liver

Tumor Cells by a Cell Permeable Gamma Guanidine-based Peptide Nucleic Acid. Curr Cancer Drug Targets. 2013 Oct;13(8):867-78

52. Criscimanna A, Duan D, Rhodes JA, Fendrich V, Wickline ED, Hartman DJ, Monga SP,

Lotze M, Gittes GK, Fong GH, Esni F. PanIN-specific regulation of Wnt signaling by HIF2. Cancer Res. 2013 Aug 1;73(15):4781-90.


53. Nakamura I, Fernandez-B MG, Ortiz-Ruiz MC, Almada LL, Hu C, Elsawa SF, Mills LD, Romecin PA, Gulaid KH, Moser CD, Han JJ, Vrabel A, Hanse EA, Akogyeram NA, Albrecht JH, Monga SP, Sanderson SO, Prieto J, Roberts LR, Fernandez-Z ME. Activation of Transcription Factor GLI1 by WNT Underlies the Role of SULFATASE 2 as a Regulator of Tissue Regeneration. J Biol Chem. 2013 Jul 19;288(29):21389-98.

54. Wickline E, Du Y, Stolz DB, Kahn M, Monga SP. γ-Catenin at adherens junctions: Mechanism and biological implications in hepatocellular cancer after β-catenin knockdown. Neoplasia. 2013 Apr;15(4):421-34.

55. Awuah P, Nejak-Bowen KN, Monga SP. Role and regulation of PDGFRα in liver

development and regeneration. Am J Pathol. 2013 May;182(5):1648-58 56. Pullara F, Guerrero-Santoro J, Calero M, Zhang Q, Peng Y, Spahr H, Kornberg GL,

Cusimano A, Stevenson HP, Santamaria H, Reynolds SL, Brown IS, Monga SP, Houten BV, Rapic-Otrin V, Calero G, Levine AS. A general path for large-scale solubilization of cellular proteins: From membrane receptors to multiprotein complexes. Protein Expr Purif. 2013 Feb;87(2):111-9.

57. Nejak-Bowen KN, Kikuchi A, Monga SP. β-Catenin-NF-κB interactions in murine

hepatocytes: A complex to die for. Hepatology 2013 Feb;57(2):763-74. 58. Awuah PK, Rhieu BH, Singh S, Misse A, Monga SP. β-Catenin Loss in Hepatocytes

Promotes Hepatocellular Cancer after Diethylnitrosamine and Phenobarbital Administration to Mice. PLoS One. 2012;7(6):e39771.

59. Lade A, Ranganathan S, Luo J, Monga SP. Calpain Induces N-terminal Truncation of β-

Catenin in Normal Murine Liver Development: Diagnostic implications in hepatoblastomas. J Biol Chem. 2012 Jun 29;287(27):22789-98.

60. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH, Monga SP, Geller DA, Lotze

MT, Tsung A. High mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. Hepatology. 2012 Jun;55(6):1863-75.

61. Liu S, Yeh TH, Singh VP, Shiva S, Krauland L, Li H, Zhang P, Kharbanda K, Ritov V, Monga

SP, Scott DK, Eagon PK, Behari J. β-catenin is essential for ethanol metabolism and protection against alcohol-mediated liver steatosis in mice. Hepatology. 2012 Mar;55(3):931-40.

62. Thompson MD, Wickline ED, Bowen WB, Lu A, Singh S, Misse A, Monga SP. Spontaneous

repopulation of β-catenin null livers with β-catenin-positive hepatocytes after chronic murine liver injury. Hepatology. 2011 Oct;54(4):1333-43

63. Wickline E, Awuah PK, Behari J, Ross M, Stolz DB, Monga SP. Hepatocyte Gamma-Catenin

Compensates for Conditionally deleted Beta-Catenin at Adherens Junctions. J Hepatol. 2011 Dec;55(6):1256-62.

64. Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP, Waltz SE. β-Catenin is

required for Ron receptor-induced mammary tumorigenesis. Oncogene. 2011 Aug 25;30(34):3694-704.


65. Thompson MD, Dar MJ, Monga SP. Pegylated interferon-alpha targets Wnt signaling by inducing nuclear export of beta-catenin. J Hepatol. 2011 Mar;54(3):506-12.

66. Yeh TH, Krauland L, Singh V, Zou B, Devaraj P, Stolz DB, Franks J, Monga SP, Sasatomi E,

Behari J. Liver-specific beta-catenin knockout mice have bile canalicular abnormalities, bile secretory defect, and intrahepatic cholestasis. Hepatology. 2010 Oct;52(4):1410-9.

67. Thompson MD, Awuah P, Singh S, Monga SP. Disparate cellular basis of improved liver repair in beta-catenin overexpressing mice after long-term DDC exposure. American Journal of Pathology, 2010 Oct;177(4):1812-22.

68. Zhang X, Tan X, Zeng G, Misse A, Singh S, Kim Y, Klaunig J, Monga SP. Conditional β-

catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and PDGFRα/PIK3CA signaling. Hepatology, 2010 Sep;52(3):954-65.

69. Nejak-Bowen KN, Thompson MD, Singh S, Bowen WC, Dar MJ, Khillan J, Dai C, Monga SP.

Accelerated liver regeneration & hepatocarcinogenesis in mice overexpressing serine-45 mutant β-catenin. Hepatology, 2010 May;51(5):1603-13.

70. Behari J, Yeh TH, Krauland L, Otruba W, Cieply B, Hauth B, Apte U, Wu T, Evans R, Monga

SP. Liver specific β-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol. 2010 Feb;176(2):744-53. Epub 2009 Dec 17.

71. Prince JM, Vodovotz Y, Baun MJ, Monga SP, Billiar TR, Gerlach JC. The Nitric Oxide Donor

S-nitrosoglutathione (GSNO) Reduces Apoptotic Primary Liver Cell Loss in a 3D Perfusion Bioreactor Culture Model Developed for Liver Support. Tissue Eng Part A. 2010 Mar;16(3):861-6.

72. Nejak-Bowen KN, Zeng G, Tan X, Cieply B, Monga SP. Beta-catenin regulates vitamin C

biosynthesis and cell survival in murine liver. J Biol Chem. 2009 Oct 9;284(41):28115-27. 73. Apte UA, Singh S, Zeng G, Cieply B, Virji M, Wu T and Monga SP. β-Catenin activation

promotes liver regeneration after acetaminophen-induced liver injury. Am J Pathol. 2009 Sep;175(3):1056-65.

74. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/{beta}-Catenin Signaling

Promotes Podocyte Dysfunction and Albuminuria. J Am Soc Nephrol. 2009 Sep;20(9):1997-2008.

75. Apte U, Gkretsi V, Bowen WC, Mars WM, Luo JH, Donthamsetty S, Orr A, Monga SP, Wu C,

Michalopoulos GK. Enhanced LR following changes induced by hepatocyte-specific genetic ablation of ILK. Hepatology. 2009 Sep;50(3):844-51.

76. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y Wnt/beta-catenin signaling promotes renal

interstitial fibrosis. J Am Soc Nephrol. 2009 Apr;20(4):765-76. 77. Cieply B, Zeng G, Singh T-P, Geller DA, Monga SP. Unique phenotype of hepatocellular

cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009 Mar;49(3):821-31


78. Tan X, Yuan, Y, Zeng G, Apte U, Thompson M, Cieply B, Stolz D, Michalopoulos GK, Kaestner KH, Monga SP. β-Catenin deletion in hepatoblasts disrupts hepatic morphogenesis and survival during mouse development. Hepatology. 2008 May;47(5):1667-79.

79. Zeng G, Apte U, Cieply B, Monga SP. siRNA-mediated β-catenin knockdown in human

hepatoma cells results in decreased growth and survival. Neoplasia. 2007 Nov;9(11):951-9. 80. Sharrow AC, Li Y, Micsenyi A, Griswold RD, Wells A, Monga SP, Blair HC. Modulation of

osteoblast gap junction connectivity by serum, TNFalpha, and TRAIL. Exp Cell Res. 2008 Jan 15;314(2):297-308.

81. Guo D, Sarkar J, Suino-Powell K, Xu Y, Matsumoto K, Jia Y, Yu S, Khare S, Haldar K, Rao

MS, Foreman JE, Monga SP, Peters JM, Xu HE, Reddy JK. Induction of nuclear translocation of CAR by PPARalpha synthetic ligands in mouse liver. J Biol Chem. 2007 Dec 14;282(50):36766-76. Epub 2007 Oct 25.

82. Apte U, Thompson M, Cui S, Liu B, Cieply B, Monga SP. Wnt/β-catenin signaling mediates

oval cell response in rodents. Hepatology. 2008 Jan;47(1):288-95. 83. Muller P, Monga DK, Tan X, Micsenyi A, Loizos N, Monga SP. PDGFRα: A novel therapeutic

target in HCC. Molecular Cancer Therapeutics, 2007 Jul;6(7):1932-41. 84. Apte U, Zeng G, Thompson M, Muller P, Micsenyi A, Cieply B, Kaestner KH, Monga SP. β-

Catenin is critical for early postnatal liver growth. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1578-85.

85. Behari J, Thompson M, Muller P, Zeng G, Micsenyi A, Sekhon S, Leoni L and Monga SP. R-

Etodolac decreases β-catenin levels along with survival and proliferation of hepatoma cells. J Hepatol. 2007 May;46(5):849-57.

86. Zeng G, Apte U, Micsenyi A, Cieply B, Gandhi C, Demetrius A, Monga SP. Wnt’er in Liver:

expression of Wnt and frizzled genes in mouse. Hepatology. 2007 Jan;45(1):195-204. 87. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. Beta-catenin knockout reveals its

role in liver growth and regeneration. Gastroenterology. 2006 Nov;131(5):1561-72. (Accompanying Editorial).

88. Apte U, Micsenyi A, Muller P, Zeng G, Kaestner K, Monga SP. Role of β-catenin in HGF-

induced hepatomegaly in mice. Hepatology. 2006 Oct;44(4):992-1002. 89. Luo JH, Ren B, Keryanov S, Tseng GC, Rao U, Monga SP, Strom S, Demetris AJ, Nalesnik

M, Yu YP, Ranganathan S and Michalopoulos GK. Transcriptomic and Genomic analysis of Human Hepatocellular Carcinomas and Hepatoblastomas. Hepatology 2006 Oct;44(4):1012-24.

90. Zeng G, Apte U, Micsenyi A, Bell A, Monga SP. Tyrosine residues 654 & 670 in β-catenin

are crucial in regulation of Met-β-catenin interactions. Exp Cell Res. 2006 Aug 10. (Highlight Section)


91. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, Kokkinakis DM, Monga SP. Aberrant Wnt/β-Catenin Signaling In Pancreatic Adenocarcinoma. Neoplasia 2006, April:8(4):279-289.

92. Monga SP, Micsenyi A, Germinaro M, Apte UM, Bell A. Beta-catenin regulation during

matrigel-induced rat hepatocyte differentiation. Cell Tissue Res. 2006 Jan;323(1):71-9. Epub 2005 Sep 14.

93. Monga SP, Hout, M, Baun, M, Micsenyi A, Muller P, Tummalapalli, Ranade, AR, Luo JH,

Strom SC, Gerlach JC. Mouse fetal Liver Cells in artificial capillary beds in 3-D four-compartment bioreactors. American Journal of Pathology Am J Pathol. 2005 Nov;167(5):1279-92. (Cover Photo).

94. Ranganathan, S, Tan, X, Monga SP. β-Catenin and Met deregulation in childhood

hepatoblastomas. Pediatric and Developmental Pathology. Pediatr Dev Pathol. 2005 Jul-Aug;8(4):435-47. Epub 2005 Oct 5.

95. Tan X, Apte U, Micsenyi A, Kotsagrelos E, Luo JH, Ranganathan S, Monga DK, Bell A,

Michalopoulos GK, Monga SP. EGFR: A novel target of the wnt/β-catenin pathway in liver. Gastroenterology. 2005 Jul;129(1):285-302.

96. Sodhi D, Micsenyi A, Bowen WC, Monga DK, Lopez Talavera JC, Monga SP. Morpholino oligonucleotide-triggered β-catenin knockdown compromises normal liver regeneration. J Hepatol. 2005 Jul;43(1):132-41

97. Sekhon SS, Tan X, Micsenyi A, Bowen WC, Monga SP. FGF enriches the embryonic liver

cultures for hepatic progenitors. The American Journal of Pathology. Am J Pathol. 2004 Jun;164(6):2229-40.

98. Kohler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of

Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology. 2004 Apr;39(4):1056-65.

99. Micsenyi A, Tan X, Sneddon T, Michalopoulos GK, Monga SP. β-Catenin is Temporally

Regulated During Normal Liver Development. Gastroenterology 2004 Apr;126(4):1134-46

100. Hussain SZ, Tan X, Micsenyi A, Sneddon, T, Michalopoulos GK, Monga, SP. Wnt impacts growth and differentiation in ex vivo liver development. Exp Cell Res. 2004;292(1):157-169. (COVER PHOTO) (HIGHLIGHT SECTION)

101. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, Michalopoulos GK. Beta-catenin

antisense studies in embryonic liver cultures: role in proliferation, apoptosis, & lineage specification. Gastroenterology. 2003 Jan;124(1):202-16. (COVER PHOTO)

102. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R,

Michalopoulos GK. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res. 2002 Apr 1;62(7):2064-71.


103. Pediaditakis P, Monga SP, Mars WM, Michalopoulos GK. Differential mitogenic effects of single chain hepatocyte growth factor (HGF)/scatter factor and HGF/NK1 following cleavage by factor Xa. J Biol Chem. 2002 Apr 19;277(16):14109-15.

104. Bhanumathy CD, Tang Y, Monga SP, Katuri V, Cox JA, Mishra B, Mishra L. Itih-4, a

serine protease inhibitor regulated in interleukin-6-dependent liver formation: role in liver development and regeneration. Dev Dyn. 2002 Jan;223(1):59-69.

105. Pediaditakis P, Lopez-Talavera JC, Petersen B, Monga SP, Michalopoulos GK. The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat. Hepatology. 2001 Oct;34(4 Pt 1):688-93.

106. Weinstein M, Monga SP, Liu Y, Brodie SG, Tang Y, Li C, Mishra L, Deng CX. Smad

proteins & HGF control parallel regulatory pathways that converge on β1-integrin to promote liver development. Mol Cell Biol. 2001 Aug;21(15):5122-31.

107. Monga SP, Pediaditakis P, Mule K, Stolz DB, Michalopoulos GK. Changes in WNT/beta-

catenin pathway during regulated growth in rat liver regeneration. Hepatology. 2001 May;33(5):1098-109. (COVER PHOTO)

108. Monga SP, Tang Y, Candotti F, Rashid A, Wildner O, Mishra B, Iqbal S, Mishra L.

Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants. Cell Transplant. 2001 Jan-Feb;10(1):81-9.

109. Monga SP, Wadleigh R, Sharma A, Adib H, Strader D, Singh G, Harmon JW, Berlin M, Monga DK, Mishra L. Intratumoral therapy of cisplatin/epinephrine injectable gel for palliation in patients with obstructive esophageal cancer. Am J Clin Oncol. 2000 Aug;23(4):386-92.

110. Mishra L, Cai T, Yu P, Monga SP, Mishra B. Elf3 encodes a novel 200-kD beta-spectrin:

role in liver development. Oncogene. 1999 Jan 14;18(2):353-64. 111. Mishra L, Yu P, Cai T, Monga SP, Mishra B. Genomic structure, chromosomal mapping,

and muscle-specific expression of a PH domain-associated intronless gene, cded/lior. Mamm Genome. 1999 Jan;10(1):62-7.

112. Monga SP, Wadleigh R, Adib H, Harmon JW, Berlin M, Mishra L. Endoscopic treatment

of gastric cancer with intratumoral cisplatin/epinephrine injectable gel: a case report. Gastrointest Endosc. 1998 Oct;48(4):415-7.

113. Cai T, Yu P, Monga SP, Mishra B, Mishra L. Identification of mouse itih-4 encoding a

glycoprotein with two EF-hand motifs from early embryonic liver. Biochim Biophys Acta. 1998 May 29;1398(1):32-7.

114. Mishra L, Tully RE, Monga SP, Yu P, Cai T, Makalowski W, Mezey E, Pavan WJ, Mishra

B. Praja1, a novel gene encoding a RING-H2 motif in mouse development. Oncogene. 1997 Nov 6;15(19):2361-8.


Reviews, invited published papers, proceedings of conference and symposia, monographs, books and book chapters (Selected) Reviews 1. Monga SP. Liver regeneration in 2018. Updates on hepatic homeostasis and the many

tiers of hepatobiliary repair. Nat Rev Gastroenterol Hepatol. 2018 Dec 10. doi: 10.1038/s41575-018-0090-x. [Epub ahead of print] PMID:30531815

2. Russell, JO, Monga SP. Wnt/β-catenin signaling in liver pathobiology. Annu Rev Pathol.

2018 Jan 24;13:351-378. doi: 10.1146/annurev-pathol-020117-044010. Epub 2017 Nov 10. PMID: 29125798

3. Preziosi ME, Monga SP. Update on the Mechanisms of Liver Regeneration. Semin Liver

Dis. 2017 May;37(2):141-151. doi: 10.1055/s-0037-1601351. Epub 2017 May 31. 4. Soto-Gutierrez A, Gough A, Vernetti LA, Taylor DL, Monga SP. Pre-clinical and clinical

investigations of metabolic zonation in liver diseases: The potential of microphysiology systems. Exp Biol Med (Maywood). 2017 Jan 1:1535370217707731. doi: 10.1177/1535370217707731.

5. Monga SP. β-Catenin signaling and roles in liver homeostasis, injury and tumorigenesis.

Gastroenterology 2015 Jun;148(7):1294-1310. 6. Kikuchi A, Monga SP. PDGFRα in Liver Pathophysiology: Emerging Roles in

Development, Regeneration, Fibrosis, and Cancer. Gene Expr. 2015;16(3):109-27. 7. Monga SP. Role and Regulation of β-Catenin Signaling During Physiological Liver

Growth. Gene Expression. Gene Expr. 2014;16(2):51-62. 8. Shin D, Monga SP. Cellular and Molecular Basis of Liver Development. Comprehensive

Physiology. Compr Physiol. 2013 Apr 1;3(2):799-815. 9. Lade AG, Monga SP. Beta-catenin signaling in hepatic development and progenitors:

Which way does the WNT blow? Dev Dyn. 2011 Mar;240(3):486-500. 10. Nejak-Bowen K, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular

cancer: Sorting the good from the bad. Semin Cancer Biol. 2011 Feb;21(1):44-58. Epub 2010 Dec 21.

11. Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem

Cell Biol. 2009 Sep 9. 12. Nejak-Bowen K, Monga SP. Wnt/β-catenin signaling in hepatic organogenesis. Review.

Organogenesis. 2008 (April/May/June);4(2): 92-99 13. Thompson, M, Monga SP. Wnt/β-catenin signaling in Liver Health and Disease. Review.

Hepatology. 2007 May;45(5):1298-305.


14. Monga SP, Gerlach JC. Human fetal hepatocyte behavior in dynamic 3-D perfusion bioreactor culture. Invited Review. J of Organ Dysfunction. March 08, 2007. 1-10 (iFirst article).

Editorials 1. Ko S, Monga SP. Hepatic zonation now on hormones! Hepatology. 2018 Aug 18. doi:

10.1002/hep.30221. [Epub ahead of print] PubMed PMID: 30120897.

2. Preziosi M, Monga SP. Novel genetic activation screening in liver repopulation and cancer; Now crispr than ever! Hepatology. 2018 May 9. doi: 10.1002/hep.30084. [Epub ahead of print] PubMed PMID: 29742805.

3. Monga SP. Lipid metabolic reprogramming in hepatic ischemia-reperfusion injury. Nat

Med. 2018 Jan 9;24(1):6-7. doi: 10.1038/nm.4468. PubMed PMID: 29315298.

4. Monga SP. Hepatic Regenerative Medicine: Exploiting the Liver's Will to Live. Am J Pathol. 2014 Feb;184(2):306-8.

5. Nejak-Bowen KN, Monga SP. Wnt drives Stem cell-mediated repair response after

hepatic injury. (Hepatology Elsewhere). Hepatology 2013. 2013 Jun 20. 6. Awuah P, Monga SP. Cell cycle-related Kinase links androgen receptor & β-catenin

signaling in HCC: Why men are at a loss? (Hepatology Elsewhere) Hepatology. 2012 Mar;55(3):970-4.

7. Monga SP. Hepatic Adenomas: Presumed Innocent Until Proven Beta-catenin Mutated!

Hepatology, March 2006. (Invited Editorial). Textbook Editor 1. Editor. Monga SP. Molecular Pathology of Liver Diseases. Springer. Edition 1 (Volume

5). December 2010. Textbook Section Editor 1. Section Editor. Hepatobiliary Pathobiology: Cellular and Molecular Mechanisms.

Linda MacManus and Richard Mitchell. Encyclopedia of Pathology and Human Disease. Elsevier. Edition 1, 2013

Book chapters 1. Monga SP. The Wnt/β-Catenin Pathway. Signaling Pathways in Liver Diseases (Ed.

Dufour and Clavein). Edition 3. Springer-2015. 2. Nejak-Bowen KN, Monga SP. Developmental Pathways in Liver Regeneration. Editor.

Apte UA. Liver Regeneration: Basic Mechanisms, Relevant Models and Clinical Application. Fall 2014.


3. Thompson MD, Nejak-Bowen K, Monga SP. Targeting the Wnt Pathway in Cancer. Eds. Goss and Kahn. Springer 2011.

4. Lade A, Monga SP. Signaling Pathways. Editor. Monga SP. Molecular Pathology of Liver

Diseases. Springer. Edition 1 (Volume 5). December 2010. 5. Monga SP, Behari J. Molecular Basis of Liver Disease. Essential Concepts in Molecular

Pathology (Ed. Coleman and Tsongalis). Academic Press-2010. 6. Monga SP. The Wnt/β-Catenin Pathway. Signaling Pathways in Liver Diseases (Ed.

Dufour and Clavein). Edition 2. Springer-2010. 7. Monga SP, Jaideep Behari. Molecular basis of Liver Disease. “Molecular Pathology”(ed

Coleman and Tsongalis). Elsevier-2009. 8. Monga, SP, Michalopoulos, GK. Wnt/β-catenin signaling in Liver. “Signaling in Liver

Diseases” (ed Jean Dufour and P-A Clavien). Springer-2005. 9. Mars, W., Liu, Y. and Monga, SP. Hepatocyte Growth Factor and its Receptor, Met in

“The Cytokine Handbook” (ed. Angus W. Thomson and Michael T. Lotze), 4th edition, Elsevier Science Ltd., (May 2003).

Published abstracts (partial list) 1. Prince Awuah, Kari Nejak-Bowen, and Monga SP. Role of PDGFR{alpha} in liver

regeneration using hepatocyte specific knockout mice. FASEB J March 29, 2012 26:274.9

2. Jung Min Lee, Sucha Singh, and Monga SP. Role of glutamine synthetase as a

surrogate marker in predicting {beta}-catenin mutated hepatoceullar carcinoma. FASEB J March 29, 2012 26:145.16

3. Emily Diane Wickline and Monga SP. Structural and functional implications of

plakoglobin compensation due to {beta}-catenin loss in the liver. FASEB J March 29, 2012 26:145.15

4. Evan R Delgado and Monga SP. Elucidating the role of {beta}-catenin in hepatocellular

tumor angiogenesis. FASEB J March 29, 2012 26:48.5 5. Evan R Delgado, Raman Bahal, Danith Ly, and Monga SP. Antisense oligonucleotide

therapy: combating aberrant {beta}-catenin in hepatocellular carcinoma using peptide nucleic acids without transfecting agents. FASEB J March 29, 2012 26:397.5

6. Evan R Delgado, Gabriela Mustata, and Monga SP. Development of novel small

molecules targeting {beta}-catenin driven hepatocellular carcinoma. FASEB J March 29, 2012 26:405.3

7. Monga SP, Amalea Misse, Emelio Ramos, and Tomas Ganz. Cell proliferation in liver in

response to iron overload is dependent on {beta}-catenin in male mice. FASEB J March 29, 2012 26:145.3


8. Jing Yang, Amalea Misse, and Monga SP. {beta}-Catenin suppression induces CYP2b10 expression by activating CAR activity. FASEB J March 29, 2012 26:145.2

9. Prince Awuah, Amalea Misse, and Monga SP. Platelet Derived Growth factor Receptor

{alpha} (PDGFR{alpha}) in Liver Development. FASEB J March 29, 2012 26:145.1 10. Maura Fanti, Andrea Perra, Monica Pibiri, Michael Schwartz, Monga SP, GM Ledda-

Columbano, and Amedeo Columbano. Wnt/{beta}-catenin pathway is activated by thyroid hormone and is required for its hepatomitogenic activity. FASEB J March 29, 2012 26:134.1

11. Emily Diane Wickline and Monga SP. β-Catenin conditional loss in hepatocytes leads to

compensatory changes in tight junctions but not in desmosomal proteins FASEB J March 17, 2011 25:242.2

12. Kari Nejak-Bowen and Monga SP. Hepatic β-catenin loss protects from TNF{alpha}-

mediated injury and death FASEB J March 17, 2011 25:359.2 13. Kari Nejak-Bowen and Monga SP. Paradoxical protection to Fas-induced hepatic injury in

β-catenin conditional knockout mice FASEB J March 17, 2011 25:366.7 14. Emily Diane Wickline, Prince Awuah, and Monga SP. Loss of {beta}-catenin in

hepatocyte-specific knockouts is compensated by {gamma}-catenin at the adherens junctions FASEB J March 17, 2011 25:442.5

15. Evan Delgado, Harshitha Mannam, Stephen Strom, Gabriela Mustata, and Monga SP.

Identification of novel chemotypes targeting β-catenin in hepatocellular carcinoma. FASEB J March 17, 2011 25:442.7

16. Prince Awuah, Xufeng Zeng, and Monga SP. PDGFR{alpha}: A major escape pathway

following {beta}-catenin suppression. FASEB J March 17, 2011 25:442.8 17. Mohd Jamal Dar and Monga SP. Regucalcin mediated up-regulation of Wnt/{beta}-

catenin signaling FASEB J March 17, 2011 25:914.2 18. Abigail Lade and Monga SP. Role of HGF phosphorylation of beta-catenin at Y654 in

embryonic mouse liver development FASEB J March 17, 2011 25:998.4 19. Antonella Cusimano, Kari Nejak-Bowen, and Monga SP. Non-canonical Wnt signaling

during liver regeneration FASEB J March 17, 2011 20. Antonella Cusimano and Monga SP. Changes in desmosomal proteins during liver

regeneration after mouse partial hepatectomy FASEB J March 17, 2011 25:791.2 21. Kari Nichole Nejak-Bowen, Michael Thompson, and Monga SP. Activation of the

Wnt/{beta}-catenin pathway leads to enhanced proliferation and liver regeneration in mice FASEB J April 6, 2010 24:236.1

22. Michael D Thompson, Sucha Singh, and Monga SP. Role for {beta}-catenin in repair of

biliary injury after exposure to DDC FASEB J April 6, 2010 24:236.8


23. Mohd Jamal Dar, Michael D Thompson, and Monga SP. Pegylated interferon 2-alpha mediated down-regulation of Wnt/beta-catenin pathway via up-regulation of nuclear export factor RanBP3 FASEB J April 6, 2010 24:354.10

24. Prince Awuah, Emily Wickline, and Monga SP. Loss of Beta-Catenin leads to

compensatory changes in adherens and other junctions FASEB J April 6, 2010 24:348.1

25. Xufeng Zhang and Monga SP. β-Catenin and PDGFRα signaling: Two Divergent

mechanisms of hepatocellular carcinoma FASEB J April 6, 2010 24:349.4 26. Michael D Thompson, Sucha Singh, and Monga SP. Repopulation of {beta}-catenin null

liver with {beta}-catenin positive progenitor cells and tumor formation after long-term exposure to DDC FASEB J April 6, 2010 24:349.6

27. Kari Nichole Nejak-Bowen, Xinping Tan, Chunsun Dai, and Monga SP. Apoptosis in

{beta}-catenin knockout mice occurs through the Fas pathway. FASEB J April 6, 2010 24:565.10

28. Xufeng Zhang and Monga SP. β-Catenin loss promotes DEN-induced liver cancer via

oxidative stress & PDGFRα/PI3K signaling. FASEB J April 6, 2010 24:421.6 29. Abigale G. Lade and Monga SP. Non-canonical Wnt Signaling in Embryonic Liver

Development. FASEB J April 6, 2010 24:749.1 30. Kari Nichole Nejak-Bowen and Monga SP. Improved transplantation efficiency

hepatocytes expressing Ser45-mutated-β-catenin FASEB J April 6, 2010 24:749.2 31. Kari Nichole Nejak-Bowen, Xinping Tan, and Monga SP. β-Catenin knockout mice are

protected from TNFα mediated apoptosis FASEB J April 6, 2010 24:38.5 32. Abigail G. Lade and Monga SP. A Truncated β-catenin Species Promotes Hepatocyte

Differentiation in Late Embryonic Liver Development. FASEB J April 6, 2010 24:39.7 33. Michael D Thompson and Monga SP. Potential role for beta-catenin in oval cell

differentiation during liver injury repair FASEB J April 22, 2009 23:117.9 34. Kari D Nejak-Bowen, Xinping Tan, and Monga SP Paradoxical roles of β-catenin in Fas

and TNF-alpha-mediated hepatocyte death FASEB J April 22, 2009 23:235.3 35. K Nejak-Bowen & Monga SP. Regeneration advantage in β-catenin transgenic mice after

partial hepatectomy FASEB J April 22, 2009 23:741.11 36. Gang Zeng, Kari-Nejak Bowen, and Monga SP. SMP30/Regucalcin is a direct

transcriptional target of Wnt signaling in liver FASEB J April 22, 2009 23:741.14 37. Sarangarajan Ranganathan, Sucha Singh, and Monga SP. Immunohistochemicaanalysis

of beta-catenin, glutamine synthetase and cyclin-D1 in hepatoblastomas FASEB J April 22, 2009 23:741.16


38. Gang Zeng and Monga SP. Beta-catenin/TCF complex regulates HNF4-alpha expression in the liver FASEB J April 22, 2009 23:359.2

39. Weichun He, Chunsun Dai, Yingjian Li, Gang Zeng, Monga SP, and Youhua Liu. A role

of Wnt/beta-catenin signaling in the pathogenesis of renal interstitial fibrosis FASEB J April 22, 2009 23:359.3

40. Xufeng Zhang, Xinping Tan, and Monga SP. Loss of β-catenin accelerates N-

nitrosodiethylamine-Induced Hepatocarcinogenesis by Activating Phosphoinositide 3-Kinase (PI3K)/Akt Signaling Pathway FASEB J April 22, 2009 23:359.4

41. Michael D Thompson and Monga SP. Increased oval cell response and fibrosis in beta-

catenin null livers after long-term DDC exposure FASEB J April 22, 2009 23:363.5 42. Michael D Thompson and Monga SP. Pegylated interferon-alpha targets beta-catenin by

inducing its nuclear export FASEB J April 22, 2009 23:438.3 43. Cieply B, Monga SP. β-Catenin expression in Pediatric Malignancies. FASEB J; April

2008: A118#1124.9 44. Apte U, Stolz D, Monga SP. Interactions of β-catenin with Met and E-cadherin during oval

cell activation. FASEB J; April 2008: A113#1124.4 45. Cieply B, Monga SP. Using tyrosine-654 phosphorylation of β-catenin to predict HCC

pathology. FASEB J; April 2008: A116#1124.7 46. Thompson M, Zeng G, Cieply B and Monga SP. Pegylated interferon attenuates Wnt/β-

catenin signaling in HCC. Hepatology, October 2007; 639. 47. Behari J, Monga SP. Loss of β-catenin excerbates MCD-induced steatohepatitis in mice.

Hepatology, October 2007; 1190. 48. Nejak-Bowen K, Zeng G, Monga SP. Regucalcin is a novel target of beta-catenin in liver.

867.7, FASEB J. April 2007. 49. Zeng G, Apte U, Cieply B, Monga SP. siRNA-mediated β-catenin knockdown in human

hepatoma cells results in their decreased growth and survival. 49.4, FASEB J, April 2007.

50. Apte U, Cui S, Liu B, Thompson M, Monga SP. Wnt/β-catenin pathway is critical for oval

cell activation in rats. 125.4, FASEB J, April 2007. 51. Thompson M, Micsenyi A and Monga SP. Pegged for destruction: beta-catenin as a

novel target of pegylated interferon. FASEB J, April 2007. 52. Behari J, Cieply B, Otruba W, Apte U, Wu T and Monga SP. Liver specific beta-catenin

knockout mice show increased liver injury in the MCD model of steatohepatitis. 381.4, FASEB J, April 2007.


53. Apte U, Zeng Z, Kaestner K and Monga SP. Beta-catenin is essential for liver regeneration following APAP-induced acute liver failure. 867.6, FASEB J, April 2007.

54. Tan X and Monga SP. Beta-catenin is a critical morphogen for gestational hepatic

development. 867.3, FASEB J, April 2007. 55. P Stock, D Monga, A Micsenyi, X Tan, Monga SP. PDGFRα is an oncofetal target in

human HCC. 867.17, FASEB J. April 2007 56. U.M. Apte, A. Micsenyi, P. Muller, B. Cieply and Monga SP. Rapid activation of beta-

catenin during liver regeneration following acetaminophen-induced acute liver failure. 886.3, FASEB J. March 2006

57. X. Tan, Y. Yuan and Monga SP. Beta-catenin is essential for normal liver development.

410.4, FASEB J. March 2006. 58. U.M. Apte, A. Micsenyi, P. Muller, B. Cieply and Monga SP. Rapid activation of beta-

catenin during liver regeneration following acetaminophen-induced acute liver failure. 886.3, FASEB J. March 2006.

59. U.M. Apte, P. Muller, F. Awan, W. Otruba, B. Cieply and Monga SP. Wnt/beta-catenin

pathway activation during normal postnatal liver growth and development. 686.2, FASEB J, March 2006.

60. F. Awan, W. Otruba, P. Muller, G. Zeng and Monga SP. Wnt’er in mouse liver. 686.3,

FASEB J, March 2006. 61. X. Tan and Monga SP. beta-Catenin is essential in normal liver growth, regeneration and

function. 686.5, FASEB J, March 2006. 62. G. Zeng, A. Bell, A. Micsenyi and Monga SP. Regulation of Met-beta-catenin interaction

in hepatocytes by tyrosine phosphorylation. 686.6, FASEB J, March 2006. 63. Monga SP and A. Micsenyi. Pegylated interferon’s anti-hepatoma effect is mediated by

beta-catenin inhibition. 686.7, FASEB J, March 2006. 64. Prince JM, Baun MJ, Vallabhaneni R, Hout MS, Vodovotz Y, Billiar TR, Monga SP,

Gerlach JC. Nitric Oxide Supports the Establishment of Primary Rat Liver Cells in a Four Compartment Bioreactor Culture Model. Regenerate World Congress on Tissue Engineering and Regenerative Medicine. Pittsburgh, PA, April, 2006.

65. Peggy Muller, Xinping Tan, Amanda Miscenyi, Benjamin Cieply, Jaideep Behari, Monga

SP. Beta-catenin is essential for normal liver growth and development. Hepatology, Volume 42, Issue S1, Pages 196A - 298A, October 2005.

66. Jaideep Behari, Peggy Muller, Amanda Miscenyi, Lorenzo Leoni, Monga SP. Beta-

catenin inhibition by cox-2-dependent and independent pathways is associatd with decreased proliferation and survival of hepatocellular carcinima cells. Hepatology, Volume 42, Issue S1, Pages 299A - 401A, October 2005.

http://www.eb2006-online.com/viewabstract.php?id=3612&PHPSESSID=f07543fef8761587d860af5e0239a3bf

http://www3.interscience.wiley.com/cgi-bin/jissue/112099833

http://www3.interscience.wiley.com/cgi-bin/jissue/112099833


67. U.M. Apte, P. Muller, X. Tan, A. Micsenyi, B. Cieply, C. Dai, Y. Liu, K.H. Kaestner and Monga SP. beta-Catenin: a principal in vivo mediator of HGF-induced liver growth. 682.4, FASEB J, March 2006.

68. P. Müller, D. K. Monga, A. M. Micsenyi, G. Zeng, N. Loizos and Monga SP. PDGFR

alpha: a novel therapeutic target in human hepatocellular cancer. 855.4, FASEB J, March 2005.

69. G. Zeng, M. Germinaro, A. Micsenyi, N. K. Monga and Monga SP. Aberrant Wnt/ beta -

catenin signaling in pancreatic adenocarcinoma in patients. 606.9, FASEB J, March 2005.

70. U. M. Apte, P. Muller, A. Micsenyi and Monga SP. Activation of Wnt/ beta -catenin

pathway during postnatal liver development. 607.2, FASEB J, March 2005. 71. U. M. Apte, A. Micsenyi and Monga SP. Modulation of Wnt/ beta -catenin pathway

following acetaminophen-induced liver injury and regeneration. 296.5, FASEB J, March 2005.

72. X. Tan and S. S. Monga. Beta-Catenin conditional knockouts reveal its role in liver growth

and regeneration. 607.5, FASEB J, March 2005. 73. U. M. Apte, C. Dai, A. Micsenyi, Y. Liu and Monga SP. Activation of beta -catenin in

HGF-induced hepatomegaly. 607.3, FASEB J, March 2005. 74. Prince JM, Baun MJ, Hout, MS, Meiers CA, Billiar TR, Monga SP, Gerlach JC. Nitric

Oxide (NO) Inhibits Liver Cell Death in a 3-Dimensional Bioreactor Culture Model. 2004 FASEB Summer Research Conferences Mechanisms of Liver Growth, Development, and Disease, Snowmass Village, CO, August, 2004.

75. Monga SP, D. S. Sodhi, D. S. Monga and J. S. Talavera. Beta -Catenin antisense

injection compromises liver regeneration in rats. 381.7, FASEB J, March 2004. 76. Monga SP, X. S. Tan and G. S. Michalopoulos. Liver specific beta -Catenin transgenic

mice reveal EGFR as a potential target. 380.3, FASEB J, March 2004. 77. Monga SP, M. S. Hout, A. S. Micsenyi, M. S. Baun and J. S. Gerlach. Mouse fetal

hepatocyte culture in 3-D artificial capillary beds in bioreactors. 144.7, FASEB J, March 2004.

78. Monga SP, S. S. Sekhon, A. S. Micsenyi and W. S. Bowen. Fgf enriches the embryonic

liver cultures for hepatic progenitors. 144.8, FASEB J, March 2004. 79. Monga SP, X. S. Tan and S. S. Ranganathan. Beta -Catenin and c-myc immunohistochemistry: diagnostic implications in hepatoblastomas. 380.6, FASEB J, March

2004. 80. Monga SP, T. Sneddon, X. Tan and G.K. Michalopoulos. Characterization of normal β-

catenin transgenic mice. 163.1, FASEB J, March 2003.


81. Monga SP, A. Micsenyi, T. Sneddon, X. Tan and G.K. Michalopoulos. Tight temporal regulation of β-catenin during normal liver development. 665.8, FASEB J, March 2003.

82. Micsenyi, A., Sneddon, T., Tan, X., Michalopoulos, GK, Monga, SP. In vivo checkpoints

maintain tight temporal regulation of β-catenin during normal liver development. Proceedings of the AACR, March 2003;44:1297.

83. Monga, DK., Tan X., Sneddon, T., Koehler, C., Michalopoulos, GK., Monga, SP.

Erythropoietin, a potent negative regulator of β-catenin in hepatocytes and liver cancer cells. Proceedings of the AACR, March 2003;44:2391.

84. Hussain S., Tan X., Sneddon, T., Michalopoulos, GK, Monga, SP. Wnt induces bile duct

formation by promoting stem cell differentiation and survival in embryonic liver cultures. The FASEB Journal 2003 (April):6259.

85. Ranganathan, S., Tan, X., Michalopoulos, G.K., Monga, SP. Beta-catenin and met

analysis in hepatoblastomas. The FASEB Journal 2003 (April). 86. Monga, SP, Tamara Sneddon, Xinping Tan, George Michalopoulos. β-Catenin transgenic

mice display hepatomegaly and pre-cancerous lesions. Suppl. To Gastroenterology, May 2003: M965.

87. Sandeep Sekhon, Xinping Tan, William Bowen, George Michalopoulos, Monga, SP.

Fibroblast Growth Factors Promote Hepatocyte Stem Cell Renewal in Embryonic Liver Cultures. Suppl. To Gastroenterology, May 2003: S946.

88. Sandeep S. Sekhon, Tamara Sneddon, William Bowen, George Michalopoulos, Monga,

SP. Selective cox-2 inhibitor in liver cancer cells: role and mechanism. Suppl. To Gastroenterology, May 2003:T984.

89. Monga, DK., Hussain, S., Tan X., Sneddon, T., Koehler, C., Michalopoulos, GK., Monga,

SP. PDGFR-α and IGFBP5 upregulation in early liver development and liver cancer cells. Suppl to Journal of Clinical Oncology, June 2003.

90. Monga, SP, Peter Pediaditakis, Aaron Bell, George K. Michalopoulos. β_Catenin

antisense studies in embryonic liver culture-role in proliferation, apoptosis and lineage specification. The FASEB Journal 2002, 16;4:291.2.

91. Monga, SP, Wendy Mars, Peter Pediaditakis, William C. Bowen, George K.

Michalopoulos. HGF induces Wnt independent nuclear translocation of β-catenin following Met-β-catenin dissociation in normal rat hepatocytes. Proceedings of the American Association of Cancer Research. March 2002;43:3317.

92. Monga, SP, Peter Pediaditakis, Christoph Koehler, Aaron Bell, George K. Michalopoulos.

β-catenin stabilization: a crucial event in hepatocyte differentiation in primary cultures. Proceedings of the American Association of Cancer Research. March 2002;43:4898.


93. Monga, SP, Wendy Mars, Peter Pediaditakis, William C. Bowen, George K. Michalopoulos. HGF induces Wnt independent nuclear translocation of β-catenin following Met-β-catenin dissociation in normal rat hepatocytes. Suppl to Gastroenterology 2002, 122;4:134.

94. Monga, SP, Wendy Mars, George K. Michalopoulos. Wnt/beta-catenin pathway during

liver regeneration, a crucial checkpoint defined in regulated growth environment. AACR (2001): 3950.

95. Monga, SP, P. Pediaditakis and G.K. Michalopoulos. HGF induces Wnt-1 independent

nuclear translocation of beta-catenin through association of c-met and beta-catenin in rat hepatocytes. AACR (2001):3725.

96. Monga, SP, T-H Kim, P. Pediaditakis and G.K. Michalopoulos. Beta-catenin modulates

cell-cell adhesion in rat liver regeneration and primary hepatocyte cultures. FASEB Journal 2000;14(4):A285.

97. Monga, SP, S. Danovitch, A. Rashid, B. Mishra, T. Fleury, L. Mishra. Correlation of

inhibition studies of elf-3, a beta-spectrin, with primary biliary cirrhosis. Gastroenterology 1999

98. Monga, SP, S. Danovitch, B. Mishra, L. Mishra. Disruption of TGF-beta signal by smad 2,

3 & ELF spectrin in Primary Biliary Cirrhosis. Hepatology 1999;30(4-2):964. 99. Monga, SP, M. Weinstein, C. Deng, L. Mishra. Essential cooperative function of TGF-

beta signaling molecules smad 2/3 for liver function can be rescued by HGF. Hepatology 1999;30(4-2):629.

100. Monga, SP, M. Weinstein, A. Rashid, L. Mishra, C. Deng. Smad 2/3 define an essential

developmental checkpoint in liver formation. Gastroenterology 1999. 101. Monga, SP, B. Mishra, D. Dhanasekhran, L. Mishra. Praja-1, a novel ring finger protein,

involved in hepatocyte apoptosis, selectively expressed in hepatocyte stem cells. Gastroenterology 1999.

102. Monga, SP, R. Wadleigh, H. Adib, D.K. Monga, J. Harman, L. Mishra. Endoscopic

intratumoral injection of cisplatin/epinephrine therapeutic injectable gel as palliative treatment for esophageal cancer. Gastroenterology 1998;114(4-2):G2660.

103. T. Cai, Monga, SP, P. Yu, B. Mishra, L. Mishra. elf, a novel beta- spectrin in liver and

bile duct development. Developmental biology 1998;198(1):67. 104. P. Yu, T. Cai, Monga, SP, B. Mishra, L. Mishra. Structure and expression of Cded, a

novel gene encoding a pH domain, maps to the distal portion of chromosome 2. Gastroenterology 1998;114(4-2):L0706.


105. Monga, SP, A. Rashid, A. Diehl, B. Mishra, L. Mishra. Functional characterization of Itih-4, a scaffolding protein isolated from developing liver. Hepatology 1998;28(4-2):38.

106. Monga, SP, A. Rahman, A. Subramanian, L.Mishra. Early liver development is heralded

by scaffolding, anchoring and trafficking proteins, important in the generation of structural and functional polarity. Hepatology 1998;28(4-2):35.

107. Monga, SP, J. Lee, H.Z. Lin, A.M. Diehl, A. Rashid, L. Mishra. PRAJA-1 and ELF cell

polarity protein from developing liver expressed at different and distinct time points during liver regeneration. Hepatology 1998;28(4-2):63.

108. Monga, SP, D. Kruse, R. Redman, B. Mishra, L. Mishra. A novel ring finger protein

PRAJA-1 is required for maintenance of developing liver architecture. Hepatology 1998;28(4-2):910.

109. Monga, SP, A. Rashid, O. Wildner, F. Condotti, B. Mishra, L. Mishra. Growth & culture

of hepatic stem cells in liver explant cultures. Dev. Biology 1998;198(1):30. 110. Monga, SP, R. Wadleigh, H. Adib, D.K. Monga, J. Harman, L. Mishra. Endoscopic

intratumoral injection of cisplatin/epi therapeutic injectable gel as palliative treatment for esophageal CA. Gastroenterology 1998;114(4-2):G2660.

111. Monga, SP, A. Rashid, O. Wildner, F. Condotti, B. Mishra, L. Mishra. Growth & culture

of hepatic stem cells in liver explant cultures. Hepatology 1998 (4-2):1763. 112. Monga, SP, A. Rashid, O. Wildner, F. Condotti, B. Mishra, L. Mishra. Growth and culture

of hepatic stem cells utilizing liver explant cultures. Developmental Biology 1998;198(1):300.

PROFESSIONAL ACTIVITIES

TEACHING

NATIONAL (non-research)

1. Balancing work and personal life: Challenging but doable! Annual ASIP meeting, EB 2009, New Orleans LA (April 2009)

2. Mentoring through the eyes of a mentor! Annual ASIP meeting, EB 2010, Anaheim, CA

(April 2010) 3. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2011,

Washington D.C (April 2011). 4. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2012, San

Diego, CA (April 2012). 5. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2013, Boston,

MA (April 2013).


6. Lunch & Learn: Collaborating with Industry: An Academic Faustian Bargain? Annual ASIP meeting at EB2013, Boston, MA (April 2013). Chairs: Richard Mitchell and Paul Monga

7. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2014, San

Diego, MA (April 2014). 8. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2015, Boston,

MA (March 2015). 9. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2016, San

Diego (April 2016). 10. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2017, Chicago

(April 2017). 11. Stem Cells Biology for High school teachers. Annual ASIP meeting at EB2018, San

Diego (April 2018). 12. Mentoring graduate students. Annual ASIP meeting at EB 2018, San Diego (April 2018). 13. ASIP member spotlight. Annual ASIP meeting at EB 2019, Orlando (April 2019)

UNIVERSITY Current teaching administration:

o Course Director, Stem Cells: 2002-present

o Course Director, Research Seminars in 2003-present

Regenerative Medicine (CATER seminars)

o Program Director 2012-present Cell & Tissue Engineering Approaches to Regeneration (CATER); NIH-funded T32 Training Program

Diversity and Career Development Teaching:

• Student of Color Dinner Lecture Series 10/2012

Advice on Grantspersonship

• NRSA F32 Grant Writing Workshop 02/2013 Office of Academic Career Development University of Pittsburgh, SOM

• Student of Color Dinner Lecture Series 01/2013 Mentor Mentee Relationship

• Career in Translational Research 09/2014 Heme-Onc Fellows Day, UPCI


• NRSA F32 Grant Writing Workshop-II 05/2015 Office of Academic Career Development University of Pittsburgh, SOM

• NRSA F32 Grant Writing Workshop-I 04/2015 Office of Academic Career Development University of Pittsburgh, SOM

• MSTP F30 Grant Writing Lecture 08/2015

• Organizer of career development workshop on 03/2016 Role of Mentors in Career Development

• Organizer of career development workshop on 03/2017

“My journey: Spotlight on junior faculty” CATER

• Mentor-Mentee Relationship workshop, Office of 11/2018 Career Development, University of Pittsburgh

Current teaching activity (Graduate School):

o Course – MSCMP 2730: Molecular Mechanisms of Tissue Growth & Differentiation (3.0 credits)

Dates of Course – January 2002 Number of Students – 8 Type of Students – Graduate Number of lectures – 1 Contact Hours – 1

o Course – MSCMP 3740: Stem Cells (2.0 credits)

Dates of Course – Fall 2002 No. of students – 14 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 2 Contact Hours – 16

o Course – MSCMP 2730: Molecular Mechanisms of Tissue Growth & Differentiation

(3.0 credits) Dates of Course – January 2003 Number of Students – 12 Type of Students – Graduate Number of lectures – 1

o Contact Hours – Course – MSCMP 3740: Stem Cells (3.0 credits) Dates of Course – Fall 2003 Number of Students – 20 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 3 Contact Hours – 40


o Course – MSCMP/BIOENG3760CRN467301: Research Seminars in Regenerative Medicine/CATER seminar series (1.0 credit) Dates of Course – Fall 2003 Number of Students – 13 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 1 Contact Hours – 8



o Course – MSCMP/BIOENG3760CRN467301: CATER Seminar Series (1.0 credit) Dates of Course – Spring 2003 Number of Students – 13 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 1 Contact Hours – 8

o Course – MSCMP 3740: Stem Cells (3.0 credits) Dates of Course – Fall 2004 Number of Students – 12 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 2 Contact Hours – 30

o Course – MSCMP/BIOENG3760CRN467301: CATER Seminar Series (1.0 credit)

Dates of Course – Fall 2004 Number of Students – 13 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 1 Contact Hours – 8


Dates of Course – January 2005 Number of Students – 12 Type of Students – Graduate Number of lectures – 1


Dates of Course – Spring 2005 Number of Students – 20 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 1 Contact Hours – 8

o Course – MSCMP 3740: Stem Cells (3.0 credits) Dates of Course – Fall 2005


Number of Students – 14 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 2 Contact Hours – 30













o Course – MSCMP/BIOENG3760CRN467301: CATER Seminar Series (1.0 credit) Dates of Course – Spring 2007 Number of Students – 14 Type of Students – Graduate (Interdisciplinary and Bioengineering)


Number of lectures – 0 Contact Hours – 8








o Course – MSCMP/BIOENG3760CRN467301: CATER Seminar Series (1.0 credit) Dates of Course – Fall 2008 Number of Students – 12 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 0 Contact Hours – 7



















Dates of Course – Spring 2011


Number of Students – 15 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 0 Contact Hours – 7




o Course – MSBMG 2525: Developmental Mechanisms of Human Disease

Date of Course – March 2011 Number of Students – 6 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of Lectures – 1 Contact Hours – 2







Dates of Course – January 2012 Number of Students – 13 Type of Students – Graduate


Number of lectures – 1

o Course – MSBMG 2525: Developmental Mechanisms of Human Disease Date of Course – March 2012 Number of Students – 6 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of Lectures – 1 Contact Hours – 2




o Course – MSCMP 2730: Molecular Mechanisms of Tissue Growth & Differentiation Dates of Course – January 2013 Number of Students – 16 Type of Students – Graduate Number of lectures – 1

o Course – MSBMG 2525: Developmental Mechanisms of Human Disease

Date of Course – March 2013 Number of Students – 3 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of Lectures – 1 Contact Hours – 2








o Course – MSBMG 2525: Developmental Mechanisms of Human Disease Date of Course – February 2014 Number of Students – 4 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of Lectures – 1 Contact Hours – 2







o Course – MSBMG 2525: Developmental Mechanisms of Human Disease Date of Course – April 2015 Number of Students – 6 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of Lectures – 1


Contact Hours – 2







o Course – MSBMG 2525: Developmental Mechanisms of Human Disease Date of Course – April 2016 Number of Students – 6 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of Lectures – 1 Contact Hours – 2














o Course – MSCMP/BIOENG3760CRN467301: CATER Seminar Series (1.0 credit) Dates of Course – Fall 2018 Number of Students – 15 Type of Students – Graduate (Interdisciplinary and Bioengineering) Number of lectures – 0


Contact Hours – 8


Past Teaching activity (Medical School):

o Course – Digestion and Nutrition; Histology & Pathology Laboratories

Dates of Course – November and December 2001 Number of students – 15 Type of Students – MS2 (class of 2004) Number of lectures – 7 Contact Hours – 7

o Course – Digestion and Nutrition, Gastroenterology

Dates of Course – November and December 2001 Number of students – 12 Type of Students – MS2 (class of 2004) Number of PBLs – 6 Contact Hours – 8

o Course – Digestion and Nutrition; Histology & Pathology Laboratories

Dates of Course – December 2002 Number of students – 50 Type of Students – MS2 (class of 2005) Number of lectures – 1 Contact Hours – 1

o Course – Digestion and Nutrition, Gastroenterology

Dates of Course – December 2004 and January 2005 Number of students – 12 Type of Students – MS2 (class of 2004) Number of PBLs – 6 Contact Hours – 8

o Course – Digestion and Nutrition, Gastroenterology Dates of Course – December 2005 Number of students – 12 Type of Students – MS2 (class of 2004) Number of PBLs – 2 Contact Hours – 3

o Course – Digestion and Nutrition, Gastroenterology Dates of Course – December 2006 Number of students – 12 Type of Students – MS2 (class of 2005) Number of PBLs – 2


Contact Hours – 3

o Course – Digestion and Nutrition, Gastroenterology Dates of Course – December 2007 Number of students – 12 Type of Students – MS2 (class of 2005) Number of PBLs – 2 Contact Hours – 3

OTHER TEACHING ACTIVITY: Service on Ph.D. student thesis committees/comprehensive exams as a member: Vlad Sandulache Pathology (CMP)/CATER 2004-2006 Vasiliki Gkretsi Pathology (CMP) 2004-2006

Timothy Maul Bioengineering/CATER 2004-2007 Christopher Shepard Pathology (CMP) 2005-2007 Xin He Pathology (CMP) 2005-2008 Kristi Kolarcik Pathology (CMP) 2006-2010 Dan Wang Pathology (CMP) 2006-2011 Bowen Liu Pathology (CMP) 2007-2010 Li Zou Bioengineering 2007-2010 Stephanie Poe Medicine 2008-2013 Matthew Brown Pathology (CMP) 2010-2014 Marc Hansel Pathology (CMP) 2010-2010 Rekha Gyanchandani Molecular Pharmacology 2012-2013

Noah Peyser Molecular Pharmacology 2013 Mehwish Khaliq Molecular Genetics 2013-2017

and Developmental Biology Anny Caceres Molecular Pharmacology 2013-2017 Collin Edington Bioengineering 2013-2014 Kellsye Fabian Immunology 2013-2017 Marion Joy Bioengineering 2013-2016

Llyod Lee Molecular Pharmacology 2014-present La Li Pathology (CMP) 2015-present

Adentunji Fayomi Molecular Genetics 2015-2018 and Developmental Biology

Ali Nagle Molecular Pharmacology 2015-2018 Service on Ph.D. external student thesis committees as member: Cindy Thomas Microbiology 2011-2014

(Stony Brook University, NY) Prital Patel Molecular Biology 2017 (University of Toronto)

Service on Ph.D. student comprehensive exam/thesis committees as chair: Saurabh Kharait Pathology 2003-2005 Kun-Wei Liu Pathology 2008-2011 Matthew Brown Pathology 2010-2014


Alison Mary Nagle Molecular Pharmacology 2015-2018 Colin Beckwitt Pathology (CMP) 2015 Elizabeth Stahl Pathology (CMP) 2016-2018 Service on faculty/fellow/postdoctoral trainee committees

Pal Kaposi-Novak, M.D. PGY2 (Pathology, PIRRT Program) 2008 Jaideep Behari, MD, PhD Asst. Prof (Medicine, K award) 2007-2012 Ricardo Costa, M.D. Hem/Onc Fellow, AGH 2010-2011 Aaron Bell, Ph.D. Asst Professor, Exp Path 2010-2012 Yanping Yu, Ph.D. Asst Professor, Exp path 2010-2012 Donghun Shin, Ph.D. Asst Professor, MGB 2010-2014 Laura Jackson PGY5 (Peds, Neonatology Fellow) 2016-2017 Bryan Brown Asst Professor, Bioengineering 2015-present Tanner Freeman, MD, PhD PGY2 (Pathology, PIRRT Program) 2017-present Kelly Bailey, MD PGY4 (Peds, Heme-Onc Fellow) 2017-present

Lab supervision of predoctoral graduate students (rotation only)

Shanshan Cui Graduate Student (IBGP) 2006 Bowen Liu Graduate Student (IBGP) 2006

Nisha Sambamurthy Graduate Student (IBGP) 2007 Erin Steer Graduate Student (IBGP) 2011

Sneha Inamdar Graduate Student (IBGP) 2011 Kevin Levin Graduate Student (MD/PhD) 2012

Greg Logan Graduate Student (IBGP) 2012 Daphne Du Graduate Student (IBGP/China) 2012 Ahmad Suhail Khazali Graduate Student (IBGP) 2013 Minwook Kim Graduate Student (IBGP) 2018 Lab supervision of predoctoral graduate students (Ph.D. training)

Peggy Muller Pathology (Pre-doctoral fellow) 2005-2006 Michael Thompson Graduate Student (IBGP, MD/PhD) 2005-2010

Kari Nejak-Bowen Graduate Student (IBGP) 2006-2011 Xu-Feng Zhang Graduate Student (China) 2008-2010 Abigale Lade Graduate Student (IBGP) 2009-2012 Prince Awuah Graduate Student (IBGP) 2008-2013 Emily Wickline Graduate Student (IBGP) 2009-2013 Evan Delgado Graduate Student (IBGP) 2010-2014 Jing (Sophie) Yang Graduate Student (IBGP) 2011-2014

Lili Zhou Graduate Student (China) 2012-2015 Alexander Kikuchi Graduate Student (IBGP, MD/PhD) 2013-2017

Morgan Preziosi Graduate Student (IBGP) 2014-2018 Jacquelyn Olivia Russell Graduate Student (IBGP) 2015-present An Jiang Graduate Student (China) 2015-2017 Qian Min Graduate Student (Wuhan University) 2016-2018 Laura Molina Graduate Student (IBGP, MD/PhD) 2017-present

Lab supervision of medical students

Melissa Lee MS-II (UPSOM) 2004


Tracey Proverbs-Singh MS-2 (UPSOM) 2007 Nicholas Maurice MS-2 (MSTP, UPSOM) 2008 Byung Han (Andrew) Rhieu MS-II (UPSOM) 2010, 2011, 2014

Lab supervision of residents

Sandeep Sekhon, M.D. Internal Medicine (PGY2, AGH, Pittsburgh) 2002-2003 Farrukh, Awan, M.D. Resident (PGY2, Internal Medicine, UPMC) 2005-2006 Manpreet Kaur, M.D. Resident (PGY2, Internal Medicine, AGH) 2006-2007

Akshta Moghe, M.D., Ph.D. Resident (PGY2, Internal Medicine, UPMC) 2015 Lab supervision of post-doctoral fellows (basic)

Dimple Sodhi, M.D. Psychology (Postdoc) 2003

Xinping Tan, Ph.D. Pathology (Post-doctoral fellow) 2003-2008 Gang Zeng, M.D., Ph.D. Pathology (Post-doctoral fellow) 2004-2009 Udayan Apte, Ph.D. Pathology (Post-doctoral fellow) 2004-2007 Mohd. Jamal Daar, Ph.D. Pathology (Research Associate) 2009- 2011 Antonella Cussimano, Ph.D. Pathology (RiMed Fellow) 2010-2012 Jung Min Lee, M.D. Pathology (Visiting Fellow) 2011-2013 Kari Nejak-Bowen, Ph.D. Pathology 2012-2013 Hirohisa Okabe, Ph.D. Pathology 2012-2014 Junyan Tao, Ph.D. Pathology 2014-2016

Tirthadipa Pradhan-Sundd Pathology 2015-present Rong Zhang Pathology 2016-2018 Na Zhan, M.D. Pathology 2016-2017

Hong Yang, M.D. Pathology 2017-present Sungjin Ko, DVM, Ph.D. Pathology 2017-2017

Supervision of post-doctoral fellows (clinical)

Sunny Hussain, M.D.,Ph.D. Pediatric Gastroenterology 2002

Dulabh K. Monga, M.D. Hematology/Oncology 2002-2003 Jaideep Behari, M.D., Ph.D. Gastroenterology 2004-2006 Tamara F. Alvarado, M.D. Pediatric Gastroenterology 2013-2015 Danielle Bell, M.D. Pediatric Hematology/Oncology 2015-2017

Akshta Moghe, M.D., Ph.D. Gastroenterology 2018-present

Supervision of Junior Faculty Junyan Tao, Ph.D. Pathology (Res. Asst. Prof) 2017-present Sungjin Ko, DVM, Ph.D. Pathology (Instructor) 2018-present

Aaron Bell, Ph.D. Pathology (Res. Asst. Prof) 2017-present Supervision of undergraduate students

Hardarshan Madan Biology (U/G- Chatham College) 2001 Emorphia Kotsegrelos Biology (SURP) 2001 Lekha Tummalapali High school senior 2004 Amanda Micsenyi Biology (SURP and U/G Lab) 2002, 2003 Matthew Germinaro Biology (SURP) 2003, 2004 Emily Boyd Biology (SURP) 2005


Amy Lu Biology 2008, 2009 Harshita Mannan High school senior 2009 Alok Paranjpee Biology 2009 Austin Cheng Biology, University of Pittsburgh 2011 Annie Gula Biology, University of Pittsburgh 2011 LaCheyla Blount SROPP student. ASIP 2014 Rosa Alcantar SROPP student, ASIP 2015 Emily Xu Biology, Raleigh Charter School 2015

Funded Laboratory Members (Past/Present)

Udayan Apte, Ph.D. Postdoctoral fellow American liver Foundation Michael Thompson GS CATER T32 (NHLBI) 09/06-07/08

Michael Thompson GS F30 (NIDDK) 08/08-07/10 Jaideep Behari, M.D., Ph.D. Assistant. Prof. of Medicine K08 (NIAAA) 07/08-06/13 Xu-Feng Zhang GS Chinese Research Council

Prince Awuah GS T32 (NIBIB) 09/09-08/11 Prince Awuah GS F31 (NIDDK) 2012-2013 Antonella Cussimano Postdoctoral fellow RiMED Fellowship Evan Delgado GS Angiogenesis T32 (NHLBI) Kari Nejak-Bowen Postdoctoral fellow American Liver Foundation Alexander Kikuchi GS ATP T32 (NHLBI), 2013-2015 Alexander Kikuchi GS F30 (NIDDK), 2015-2017 Lili Zhou GS Chinese Research Council

Morgan Preziosi GS ATP T32 (NHLBI), 2014-2016 Morgan Preziosi GS F31 (NHLBI), 2017-present

An Jiang GS Chinese Research Council Na Zhan Postdoc Chinese Research Council Qian Min GS Wuhan University Jacquelyn Russell GS CATER T32 (NIBIB), 2015-2017 Jacquelyn Russell GS F31 (NIDDK), 2017-present

Laura Molina GS CATER T32 (NIBIB) (CATER) Florencia Lorenzetti GS (Argentina) Fullbright Scholar

RESEARCH

GRANTS

1. Current Grant Support – Status: Current 05/15/2018-04/30/2022: NIDDK, NIH

Grant No. 1R01DK116993 Role in Project: M.P.I. Years: 5

SOURCE: NIH, NIDDK Percent Effort: 10%

Yearly funding: Total-$562,524; Direct-$345,972; Indirect-$216,552


Grant Title: Delineating Molecular Mechanisms Underlying Liver Progenitor Cell-Driven Liver Regeneration The main goal of this proposal is to examine the role of cholangiocytes as hepatic progenitors and signaling mechanisms that modulate their differentiation to hepatocytes

Status: Current (Pending competing renewal) 01/2004-12/2018: National Institute of Digestive Diseases and Kidney, NIH

Grant No: 1R01DK62277 Role in Project: P.I. Years: 15



Grant Title: Role of Wnt/β-catenin In Liver Development/Regeneration

The main goal of this proposal is to examine the role of β-catenin during liver development, liver regeneration using various transgenic and knockout models.

Status: Current 04/2016-03/2021: National Cancer Institute, NIH

Grant No: 1R01CA204586 Role in Project: P.I. (MPI) Years: 5

SOURCE: NIH, NCI Percent Effort: 10%

Funding Requested: Total-$427,764; Direct-$318,093; Indirect-$109,671

Grant Title: Yap-β-catenin interactions in liver pathophysiology

The main goal of this proposal is to examine the role of β-catenin and Yap interactions and biological implications in Hepatoblastoma

Status: Current 07/01/2003-08/31/2019: National Institute of Biomedical Imaging & Bioengineering, NIH

Grant No: 5T32EB001026 Role in Project: P.I. Years: 12

Source: NIH, NIBIB Percent Effort: 10% (cost-shared)

Yearly Funding: Total-$271,000

Grant Title: Cellular Approaches to Tissue Engineering and Regeneration (CATER) Predoctoral training grant for BioE & Interdisciplinary biomedical graduate students

2. Prior Grant Support – Status: Past 07/2013-06/2018: NIDDK, NIH

Grant No. 1R01DK100287-01 Role in Project: P.I. Years: 4



Grant Title: Targeting β-catenin in hepatic pathology: Novel interactions, novel paradigms.


The main goal of this proposal is to examine the role of β-catenin in liver cancer as a therapeutic target, utilizing novel in vivo and ex vivo studies and models

Status: Past 01/04/2013-03/31/2018: National Institute of Digestive Diseases and Kidney, NIH

Grant No. 1R01DK095498-01 Role in Project: P.I. Years: 5



Grant Title: Role of Platelet derived growth factor receptor-α in Liver Pathobiology

The main goal of this proposal is to examine the role of PDGFRα in liver development, regeneration and hepatic fibrosis using in vivo and ex vivo models

Status: Past 11/11/2015-11/11/2017: Corporate Research Agreement (CRA) with Abbvie

Grant No: I# 0050815 Role in Project: P.I. Years: 2

SOURCE: Abbvie Pharma. Percent Effort: 2%

Funding Requested: Total-$178,034

Grant Title: Molecular Aberrations in Liver Fibrosis

The main goal of this proposal is to examine the role of Wnt signaling in hepatic fibrosis, using genetic knockout mice

04/01/2015-03/31/2016: CRA with Dicerna Pharmaceuticals, Cambridge, MA

Grant No. I# 0048249 Role in Project: P.I. Years: 1

SOURCE: Dicerna Pharma. Percent Effort: 2%


Grant Title: Therapeutic targeting of β-catenin for treatment of hepatic pathologies. The main goal of this proposal is to test the uptake and efficacy of lipid nanoparticle based β-catenin siRNA from Dicerna Pharmaceuticals to suppress β-catenin expression in hepatic pathologies such as hepatoblastoma, HCC and cholestasis.

07/01/15-06/30/16: St. Baldrick’s Foundation Grant No. St. Baldrick’s Foundation Role in Project: Co-PI Year: 1

SOURCE: St. Baldrick’s Foundation Percent Effort: 5%

Yearly Funding: $39,973

Grant Title: Regulation of Hepatoblastoma Metabolism by Mitochondrial Sirtuins

This work could potentially identify novel targets for cancer therapies in hepatoblastoma and other human cancers.


4/1/2015 – 3/31/2016: National Institute of Health, NCI Grant Number: 1R13 CA206289 Role in Project: P.I. Year: 1

SOURCE: NIH, NCI Funding Requested: $12,000; Direct: $12,000; Indirect-$0

Grant Title: Annual ASIP meeting at Experimental Biology 2009

4/1/2014 – 3/31/2015: National Institute of Health, NCI Grant Number: 1R13 CA 196119-01 Role in Project: P.I. Year: 1

SOURCE: NIH, NCI Funding: Total-$8,000; Direct-$8,000; Indirect-$0


07/2007-06/2012: National Cancer Institute, NIH Grant No. 1R01CA124414 Role in Project: P.I. Years: 5

SOURCE: NIH, NCI Percent Effort: 35%

Funding: Total-$249,665; Direct-$172,323; Indirect-$77,342

Grant Title: Beta-Catenin as a therapeutic target in HCC.

The main goal of this proposal is to examine the role of β-catenin in liver cancer as a therapeutic target, utilizing novel in vivo and ex vivo studies and models

12/1/2006 – 11/30/2011: National Institute of Health, NHLBI

Grant No.: 1P50 HL084932 Role in Project: co-PI Years: 5

SOURCE: NIH, NHLBI Percent Effort: 5% Funding: Total-$8,808; Direct-$5,932; Indirect-$2,876

Grant Title: Host factors in fungal allergy and fibrosis.

Project IV-KGF and Inhibition of Pulmonary Fibrosis. The proposal is aimed at identifying the role of KGF in chronic lung diseases such as pulmonary fibrosis. One aim is to identify β-catenin signaling in lung injury.

02/01/2010 – 02/01/2012: RiMed Foundation Grant Number: RiMed Grant Role in Project: P.I. (Mentor) Years: 2 Funding: $75,000 Percent Effort: 9%

Grant Title: Mentorship Grant

7/1/2010 – 6/30/2011: National Institute of Health, NIDDK, NCI, NIAAA Grant Number: 1R13DK089751-01 Role in Project: P.I. Years: 1

SOURCE: NIH, NIDDK, NIAAA, NCI Funding: Total-$40,000; Direct-$40,000; Indirect-$0


Grant Title: FASEB Summer conference “Liver Growth, Injury and Metabolism: Basic

and Applied Biology”

4/1/2010 – 3/31/2011: National Institute of Health, NCI Grant Number: 1R13CA150274-01 Role in Project: P.I. Years: 1



4/1/2009 – 3/31/2010: National Institute of Health, NCI Grant Number: 1R13 CA139693 Role in Project: P.I. Years: 1



09/04-08/07: Roche Pharmaceuticals Grant Number: PEG157 Role in Project: P.I. Years: 3

SOURCE (Funded): Roche Pharmaceuticals

Grant Title: Investigate therapeutic role of Pegylated Interferon & Ribavirin in HCC

The proposal is aimed at identifying the properties of these anti-viral agents on the Wnt/beta-catenin pathway and activity using in-vitro and in-vivo models.

07/03-06/07: American Cancer Society

Grant Number: RSG-03-141-01-CNE Role in Project: P.I. Years: 4

SOURCE (Funded): American Cancer Society

Grant Title: Role of Wnt/β-catenin and HGF in Hepatocarcinogenesis

The main goal of this proposal is to examine the interactions between HGF/Met with β-catenin and how these change during liver regeneration, cancer and growth.

07/01-06/02: Department of Pathology, University of Pittsburgh Source: Pathology Postdoctoral Research Training Grant Source (PPRTP) Title: Wnt/beta-catenin in LR Years: 1

Percentage of Effort Inclusive: 100%

$ Amount: $10,000


SEMINARS AND INVITED LECTURESHIP RELATED TO RESEARCH 1. ‘Hepatic stem cell, liver development and hepatocyte transplant’ 01/2000

Department of Medicine, DMC & H, Ludhiana, Punjab, India.

2. ‘Molecular Mechanisms in Liver Development, Regeneration and 01/2001 Tumorigenesis’. Dept. of Medicine, DMC & H, Ludhiana, Punjab, India. 3. ‘Wnt/Beta-Catenin Signaling in Liver: Role in Growth and Regeneration' 04/2001

Department of Surgery, UTMB, Galveston, Texas.

4. ‘Wnt/Beta-Catenin Signaling in Liver Regeneration and Hepatocyte 05/2001 Cultures'. Department of Molecular Genetics, Ohio State University,

Columbus, Ohio. 5. ‘Wnt/β-Catenin Signaling – Role in Liver Development, Growth and 05/2001

Carcinogenesis’, Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA

6. ‘Therapeutic β-catenin inhibition: a novel strategy to control liver growth’ 11/2002 35th Annual Conference of Indian Pharmacological Society, Gwalior, India 7. ‘Therapeutic β-Catenin Inhibition: Role in Regulated and Unregulated Liver 02/2003

Growth’, Molecular Therapeutics, Drug Discovery and Therapeutics (MT/DT) seminar, University of Pittsburgh Cancer Institute, Pittsburgh. 8. ‘Role of β-catenin in Liver Development and Cancer’, UPMC Horizons 03/2003

Health System, Tumor Board Lecture (Continuing Education) 9. ‘Role of Wnt/β-Catenin in Development and Cancer’ Feist-Weiller 09/2003

Cancer Center Seminars, Louisiana State University, Shreveport, LA. 10. Role of Wnt/β-Catenin in Liver development. Environment and 02/2004

Occupational Health Department Seminar, University of Pittsburgh 11. Fetal hepatocytes in Biorectors. Experimental Biology, 2004 meeting 06/2004

ASIP, annual conference, Washington, D.C. 12. Role of Wnt/β-Catenin in Liver development. Dept. of Developmental 06/2004 Biology, University of Bath, England 13. Bioreactors in hepatic failure: From bench to bedside and back, 07/2004 Dayanand Medical College and Hospital, Ludhiana, India 14. Novel molecular targets in Hepatocellular cancer, 07/2004 Dayanand Medical College and Hospital, Ludhiana, India 15. FASEB Summer research conference 2004; Mechanisms of Liver Growth, 09/2004 Development and Disease, Snowmass, Colorado


16. Liver Seminar Series, University of Pittsburgh, SOM 01/2005 17. Beta-catenin in liver growth and development, Texas A&M, Temple, TX, 02/2005 18. Beta-catenin regulation in Liver Physiology and Pathology, University 04/2005

of Pittsburgh, 2nd Annual Pittsburgh Area Ubiquitin-Proteosome meeting. 19. Beta-catenin in Liver growth and development. University of Pittsburgh 08/2005 Cancer Institute, annual retreat, 2005 20. “Beta-catenin in Liver: Doomed if you have, doomed if you don’t!” 09/2005 Digestive Diseases Forum, Baylor College of Medicine, Houston, TX. 21. Beta-catenin in Liver Health and Disease, Science 2005, Spotlight Session- 10/2005 Growth Factors in Health and Disease, University of Pittsburgh, SOM 22. Beta-catenin is critical in normal liver growth and development, 11/2005 AASLD 2005, San Francisco, CA 23. Beta-catenin in Liver Pathobiology 03/2006 ASIP 2006, San Francisco, CA 24. Beta-catenin in Liver growth and development 04/2006 Virginia Commonwealth University, Richmond, VA 25. Beta-Catenin in Liver Development and Cancer 04/2006 University of Louisiana at Monroe, Monroe, LA 26. Beta-catenin in Liver: Doomed if you have, doomed if you don’t! 08/2006 FASEB Summer Research Conference 27. Beta-Catenin in Liver Pathobiology 11/2006 NIAAA, NIH, Bethesda, MD 28. Wnt/β-catenin Signaling Liver: Promises and Perils 01/2007 Department of Ophthalmology, UPMC 29. Novel insights into liver development and growth 03/2007 McGowan Institute of Regenerative Medicine Annual Retreat, Nemacolin 30. WNT’er in Liver: Promises and Perils 05/2007 Albert Einstein College of Medicine, Yeshiva University, NY 31. Wnt/β-catenin signaling in Liver: Promises and Perils 06/2007

Mount Sinai School of Medicine, New York

32. Wnt Signaling in Cancer 06/2007 Liver Cancer Program, Mount Sinai School of Medicine, New York

33. Wnt/β-catenin signaling in Liver Health and Disease 07/2007 Penn State University, Hershey Medical Center


34. Wnt/β-catenin signaling in Liver: Novel Roles, Novel Opportunities 09/2007 Visiting Professor, Digestive Health Center Seminar, Cincinnati Children's

35. Wnt/β-catenin in Liver, Endoderm Club Meeting 09/2007 Cincinnati Children's Hospital Medical Center

36. Novel Mechanisms in Liver Health & Disease 10/2007 Dept of Pathology, University of Pittsburgh

37. Wnt/β-catenin signaling in liver stem cells: Role in Development & Cancer 01/2008 UPCI Basic Research Seminar Series, Hillman Cancer Center, Pittsburgh 38. Beta-catenin in Liver Stem cells and development: A key player in balancing 03/2008

act! McGowan Institute of regenerative Medicine Annual retreat 2008.

39. Wnt/β-catenin signaling in Regenerative and Developmental Biology of the 04/2008 Liver. EB2008, ASIP annual meeting, San Diego, CA.

40. Wnt’er Wonderland in Liver Pathobiology: Implications in Development and 04/2008 Regeneration. Digestive Diseases Seminar, Yale University, SOM

41. Which way the Wnt blows: Stem cells in liver development & regeneration 05/2008 National Cancer Institute, NIH, Bethesda, MD 42. “Liver regeneration” lecture in course entitled ‘Frontiers in Human ES cells’ 06/2008

Woods Hole, Cape Cod, MA

43. “Wnt signaling in Liver: Novel Roles, Novel Opportunities” FASEB Summer 08/2008 Research Conference, Snowmass, CO

44. “Which way the WNT blows: Stem cells in Liver development and cancer” 09/2008 XXIX National Congress, Italian Society of Pathology, Univ of Calabria, Italy 45. “β-Catenin signaling balances proliferation & differentiation in liver growth 09/2008

& development” University of Cagliari, Cagliari, Italy

46. “Liver Stem Cells in Development and Cancer: You WNT some, you lose 10/2008 some”. Science 2008. University of Pittsburgh, SOM

47. “Stem Cell Pathways in Late Liver Development and Adults” AASLD 11/2008 Basic Research Workshop, San Francisco, CA 48. “Wnt/β-catenin signaling in Liver Stem cells: Implications in Development 11/2008 & cancer”, Research Conference, GI, Hepatology & Nutrition, UPMC 49. “β-Catenin in Hepatocellular Cancer: Pathological and Treatment 11/2008

Implications”. Department of Biology, Temple University, Philadelphia, PA 50. “Wnt Signaling in Liver Stem cells: Implications in Transplantation and 11/2008

Cancer”, International Liver Congress, EFLD2008, Cairo, Egypt


51. “Hepatic Carcinogenesis: A Wnt/beta-catenin perspective!” 11/2008 International Liver Congress, EFLD2008, Cairo, Egypt

52. “Paradoxical roles of β-Catenin in Liver Injury & Repair” 02/2009 Albert Einstein College of Medicine, Bronx, NY 54. “Beta-catenin in liver regeneration and cancer: an evolving case of 05/2009 Jekyll and Hyde” University of Chicago Medical Center, Chicago, IL 55. “Beta-catenin at the crossroads of liver regeneration and cancer” 05/2009 Kansas University Medical Center, Kansas City 56. “Molecular Pathobiology of Liver Cancer”, ASIP Summer Academy, 06/2009

Arlington,VA. Solid Tumors: Transcripts, Tyrosine Kinases & Therapeutics 57. “Wnt/β-catenin signaling at the crossroads of liver regeneration and cancer 09/2009 George Washington University Medical Center 58. “Molecular Pathogenesis of HCC: Early Morning Workshop Faculty 11/2009 AASLD 2009, Boston, MA 59. “Beta-catenin signaling and HCC: A Paradox Identified” 11/2009

Dept. of Pathology, Northwestern University, Chicago

60. “Beta-catenin signaling and HCC: A Paradox Identified” 11/2009 Dept. of Pathology, University of Pittsburgh Pathology Research Seminar

61. “β-Catenin paradox in liver regeneration and cancer” 02/2010

University of Southern Florida, Tampa, FL 62. “Wnt/β-catenin signaling in liver development” 02/2010

EASL Monothematic Conference, Amsterdam, Holland

63. “Liver Regeneration and Cancer: A Wnt/β-catenin Perspective” 03/2010 Transplant Grand Rounds, Mayo Clinic, Rochester, MN 64. “Paradox of Wnt Signaling in HCC” 03/2010 Pasteur Institute, Paris, France 65. “Hepatocellular Cancer: A Wnt/β-catenin Perspective” 04/2010 Dayanand Medical College, Ludhiana, Punjab, India 66. “Wnt/β-catenin signaling in HCC: Unveiling a Novel Paradox” 05/2010 Texas A & M Health Science Center, Austin, Tx

67. “WNT’er in liver Regenerative Medicine” 10/2010

XXX National Congress Italian Society of Pathology, Salerno, Italy

68. “β-Catenin signaling and liver regeneration in HCC: Sorting the 01/2011 good from bad”, Liver Center, University of California at San Francisco, CA


69. “Wnt/β-catenin signaling in stem cell driven tumorigenesis in liver injury” 03/2011 STC on Stem cells in liver diseases and cancer. Georgia, Atlanta

70. “β-Catenin in Liver Tumorigenesis: Novel Advances in HCC Biology” 04/2011 ASIP annual meeting, EB2011, Washington, D.C.

71. “β-Catenin signaling in liver regeneration and HCC, Sorting the good from 04/2011 the bad”, Thomas Jefferson University, Philadelphia, PA.

72. “Hepatic progenitors in development and adults: A Wnt/β-catenin 06/2011 Perspective!”, University of Cagliari, Sardinia, Italy

73. “Liver regeneration: A Wnt/Beta-catenin perspective” 06/2011 University of Cagliari, Sardinia, Italy

74. “Hepatocellular cancer, beta-catenin signaling and personalized medicine” 06/2011

University of Cagliari, Sardinia, Italy

75. “β-Catenin in liver: Promises and Perils 06/2011 Annual Pathology Retreat, University of Pittsburgh

76. “β-Catenin and liver regeneration: Story of one hero” 07/2011

SURP, University of Pittsburgh 77. “Personalized Medicine in HCC: A Wnt/β-catenin perspective” 10/2011

5th Annual RiMED scientific Symposia, Palermo, Italy

78. “Signaling Mechanisms in Liver Biology” 11/2011 Liver Down Under conference, Perth, Australia

79. “Beta-catenin signaling in liver regeneration and cancer: Uncovering a 12/2011 complex paradigm” University of Auckland, New Zealand

80. “Targeting Wnt/beta-catenin signaling in Hepatocellular Cancer: 12/2011 A Step Towards Personalized Medicine” Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan

81. “Novel paradigm in Wnt/β-catenin signaling during hepatic development” 12/2011

Annual meeting of Molecular Biology Society of Japan, Yokohama, Japan 82. “Beta-catenin signaling in liver regeneration and cancer: Sorting the Good 02/2012

from the Bad” Department of Toxicology, University of Arkansas, Little Rock

83. “Beta-catenin in Liver Pathobiology: Which way does the Wnt blow” 03/2012 Annual meeting, American Society of University Pathologists, Tortola, BVI

84. “Novel Mechanisms of Liver Tumorigenesis: Biological and Therapeutic 04/2012 Implications”. Annual ASIP meeting at EB 2012, San Diego, CA


85. “Beta-catenin signaling in liver injury and regeneration: Therapeutic 05/2012 Implications!” Cold Spring Harbor Meeting, Liver Metabolism, Diseases And Cancer, Suzhou Dushu Lake, China

86. “Wnt/beta-catenin signaling in hepatocellular cancer: Basis for 05/2012 Personalized Medicine”, Eastern Hepatobiliary Surgery Hospital, International Forum on Liver Biomarkers, Shanghai, China

87. “Beta-catenin’s role and regulation in liver: Implications in regenerative 07/2012 medicine and cancer”, University of Leipzig, Germany 88. “Beta-catenin at the interface of hepatic injury and metabolism”, 08/2012

FASEB Summer Research Conference on Liver Growth, Injury and Metabolism: Basic and Applied Biology, Snowmass, CO

88. “Beta-catenin and Liver Cancer: Implications in personalized medicine”, 09/2012

University of Parma, Italy

88. “Beta-catenin as the basis of personalized medicine in liver cancer”, 09/2012 Meeting of The Italian Society of Pathology and Translational Medicine (SIPMet), Udine, Italy

89. “Beta-catenin signaling in liver: Advances in role and regulation”, 10/2012 Albert Einstein College of Medicine, Liver Center seminar

90. “β-Catenin signaling in liver regeneration: Mechanistic and Therapeutic 11/2012 Implications”, Division of GI, University of Pittsburgh Medical Center

91. “Targeting β-catenin in hepatic pathologies”, Phase Rx, Seattle, WA 12/2012 92. “β-Catenin and liver regeneration: A Wnt-Wnt situation” 01/2013 UNC Chapel Hill, NC 93. “Wnt signaling in liver regeneration: Novel Advances and Implications 03/2013 McGowan Institute of Regenerative Medicine Annual Retreat, Nemacolin 94. “Wnt/β-catenin signaling in Hepatocellular Cancer” 03/2013 Allegheny General Hospital, Hepatobiliary Maligancies Case Conference 95. “β-Catenin in Liver Regeneration: A Wnt-Wnt Situation” 03/2013 PLUTO conference, Curacao 96. “β-Catenin Signaling in Liver Pathobiology: You Wnt some, You Lose Some” 03/2103 Inaugural Lecture, Endowed Chair for Experimental Pathology, University Of Pittsburgh, Office of Provost 97. “β-Catenin in Liver Regeneration: A Wnt-Wnt Situation” 03/2013 Basic and Translational Research in Lung Disease Conference University of Pittsburgh, School of Medicine


98. “Beta-Catenin in Liver Development and Liver Tumors” Annual ASIP 04/2013 meeting at EB 2013, Boston, MA

99. “Wnt/β-catenin signaling in liver”, Workshop on Liver and Pancreas 05/2013 Development, Function and Disease, Attica, Greece

100. Wnt/β-catenin signaling in hepatocellular cancer: Biological and 06/2013

therapeutic implications” Loyola University Medical Center, Maywood, IL 101. “β-Catenin in Liver Regeneration: A Wnt-Wnt Situation” 06/2013 University of California at San Francisco Liver Center, SF, CA 101. “β-Catenin in Liver Regeneration: A Wnt-Wnt Situation” 06/2013 Van Andel Research Institute Seminar Series, Grand Rapids, MI 102. “β-Catenin signaling in Liver Regeneration: A Wnt-Wnt Situation” 09/2013

Northeastern Ohio Medical University, Rootstown, OH 103. “β-Catenin signaling in liver pathobiology: You Wnt some, you lose some! 10/2013

Scott and White and Texas A&M, Temple, TX 104. “β-Catenin signaling in HCC: Basis of Personalized Medicine” 10/2013

SIPMET/ASIP Young Investigator Meeting, University of Rome, Rome, Italy 105. “Wnt/β-catenin signaling in hepatic regeneration”. AASLD Liver 11/2013 Regeneration Workshop, Annual AASLD Meeting, Washington DC 106. “β-Catenin and liver regeneration: A Wnt-Wnt Situation”. University of 11/2013 Toronto, Toronto, Canada 107. “Role of β-catenin in liver growth: Implications in tumorigenesis”. 11/2013 Stony Brook University, Department of Pathology, Stony Brook, NY 108. “β-Catenin, a promising therapeutic target in hepatic tumors and more” 12/2013 Drug Discovery Institute, University of Pittsburgh, PA 109. “Cellular and Molecular Circuitry of Wnt Signaling in Liver Regeneration” 01/2014 Digestive Health Center Seminar, Cincinnati Children’s, Cincinnati, OH 110. “Wnt signaling in Health and Disease”, University of Tokyo, Tokyo, Japan 01/2014 111. “Beta-catenin signaling in liver regeneration: A Wnt-Wnt situation” 01/2014 Choshu International Liver Symposium, Yamaguchi University, Japan 112. “β-Catenin and Personalized Medicine in HCC”, EASL HCC Summit, 02/2014 Geneva, Switzerland 113. “Yap and Wnt signaling in liver tumorigenesis: Novel Role”, PLUTO 03/2014 Grand Cayman Island.


114. “β-Catenin signaling in liver regeneration and homeostasis: A 04/2014 Wnt-Wnt Situation”, University of California, Riverside, CA

115. “β-Catenin signaling in liver pathobiology: You Wnt some, you lose 04/2014 some”. ASIP Outstanding Investigator Award Lecture, San Diego, CA 116. “β-Catenin signaling in liver regeneration and homeostasis: A 04/2014

Wnt-Wnt Situation”, University of California, San Diego, CA

117. “β-Catenin signaling in liver pathobiology: You Wnt some, you lose 05/2014 some”. University of Pennsylvania, Philadelphia, PA 118. “β-Catenin in Liver Pathobiology”. FASEB Summer Research Conference 07/2014

on Liver Biology: Fundamental Mechanisms and Translational Applications. Keystone, CO

119. “Cell-Molecule circuitry of Wnt signaling in liver: Implications in 07/2014 regeneration & tumorigenesis. Children’s Hospital, Pittsburgh, PA 120. “β-Catenin signaling in the liver: Implications in Pathophysiology” 07/2014 University of Florida, Gainesville, FL 121. “Wnt signaling in Liver Oncogenesis: New Interactions and Opportunuties” 09/2014

Children’s Hospital, UPMC, Pittsburgh, PA 122. “Wnt signaling in Liver Tumors”, Department of Pharmaceutical Sciences 09/2014 Seminar Series, University of Pittsburgh, PA 123. “Cell Molecule Circuitry of β-Catenin Signaling in Metabolic Zonation and 09/2014 Liver Regeneration”, Bioengineering Seminar Series, Swanson SOE, University of Pittsburgh, PA 124. “Developmental pathways in hepatic tumorigenesis: A Wnt-β-catenin 11/2014

signaling perspective”, Annual ACVP meeting, Georgia, Atlanta

125. “Developmental pathways in cancer” Van Andel Institute, 12/2014 Grand Rapids, MI

126. “Targeting β-catenin for hepatic tumors”. Dicerna Pharmaceuticals, 02/2015 Cambridge, MA 125. “Role of NPCs in hepatic homeostasis and regeneration: 03/2015

A Wnt/β-catenin perspective” ASIP annual meeting, Boston, MA 126. “β-Catenin signaling in liver pathophysiology: Implications in 04/2015

regeneration and cancer”, University of Southern California, LA, CA 125. “Cell-cell junctions, injury and repair” Cedars Sinai Hospital 04/2015

Los Angeles, CA


126. “Developmental Pathways in cancer”, St. Louis University 04/2015 St. Louis, MO

127. “Cell-cell junctions and barrier function”, Wuhan University 06/2015 Renmin Hospital, Wuhan, China 128. “β-Catenin signaling in liver tumors: basis of precision medicine” 06/2015 Shanghai Tongren Hospital, Shanghai, China 129. “Hepatic cell-cell junctions and barrier function”, Albert Einstein Hospital, 09/2015

Liver Center, New Rochelle, NY

130. “Hepatic cell-cell junctions and barrier function”, Baylor and Texas A&M 09/2015 Temple, TX, Keynote lecture

131. “Developmental Pathways in cancer: Implications in biology and 10/2015

therapy”, University of Pittsburgh Cancer Institute, Pittsburgh, PA 132. “Cell-cell junctions and barrier function: Novel insights into 10/2015

cholestatic liver disease pathogenesis”, Medical College of Wisconsin, Milwaukee, WI

133. “Cell-cell junctions and tissue barrier function”, Liver center, Kansas 10/2015 University Medical Center, Kansas City, KS 134. “Developmental Pathways in hepatic tumorigenesis: Biological and 11/2015 Therapeutic Implications.” Liver Cancer Symp, UC Davis, Sacramento, CA 135. “Wnt signaling in liver sinusoidal endothelial cells during regeneration” 11/2015 ISHSR 2015 (International Hepatic Sinusoid Meeting), Asilomar, CA, USA 136. “Wnt signaling in liver tumorigenesis.” Liver Tumors Symposia, 11/2015 Annual AASLD meeting, San Francisco, CA 137. “Cell-cell junctions and barrier function: Implications in cholestasis” 11/2015 Special seminar, UCSF, San Francisco, CA 138. “Modeling human liver tumors in mice: Biological and Therapeutic 12/2015 Implications.” Renmin Hospital, Wuhan University, Wuhan, China 139. “Modeling human liver tumors in mice: Biological and Therapeutic 12/2015

Implications”, Union Hospital, Tongji Medical College, Huazhong University, Wuhan, China

140. “Wnt/β-catenin signaling in liver regeneration” Baylor College of Medicine 02/2016 Digestive Diseases Center Symposia, Houston, TX 141. “Modeling human liver tumors in mice: Biological and therapeutic 02/2016 implications” Digestive Diseases Research Center, Washington University, St. Louis, MO


142. “To leak or not to leak: Consequences of junctional crosstalk in the liver” 03/2016 PLUTO annual meeting, San Juan, Peurto Rico 143. “Beta-catenin and Yes-associated protein in hepatoblastoma”, 03/2016 International Pediatric Liver Tumor Symposium, Houston, TX 144. “Modeling human liver tumors in mice: Biological and therapeutic 03/2016 implications”, Pitt signaling Club, University of Pittsburgh 145. “Modeling human HCC in mice”, Liver Workshop, ASIP annual 04/2016

conference Experimental Biology 2016, San Diego CA 146. “Developmental Pathways in Liver Tumorigenesis: A Wnt Perspective” 04/2016

ASPET Symposia on Wnt Signaling, Experimental Biology 2016, San Diego CA

147. “Modeling human liver tumors in mice: Biological and therapeutic 05/2016 implications”, Medical University of South Carolina, Charleston, SC 148. “Cell-cell junctions and barrier function: Implications in Liver Health 05/2016

and disease”, UC Davis, Sacramento, CA 149. “Modeling human liver tumors in mice: Implications in metabolism 05/2016

and therapy” 4th Wuhan International Conference on Cardiometabolic Science, Wuhan, China

149. “Modeling human HCC in mice: Biological and therapeutic Implications” 05/2016

Ohio State University Comprehensive Cancer Center, Columbus, OH 150. “Cell-cell junctions: Novel crosstalk and insights into cholestatic liver injury” 06/2016

FASEB Summer Research Conference, Liver Biology, West Palm Beach, FL

151. “Catenins at hepatocyte junctions: implication in cholestatic liver disease,” 08/2016 Division of Gastroenterology, Mayo Clinic, Rochester, MN.

152. “Modeling Human Liver Cancer in Mice: Biological and Therapeutic 08/2016

Implications," Pathobiology Graduate Program Retreat, Brown University, Providence, RI

153. Beta-catenin mutations in HCC: Biological and Therapeutic Implications,” 09/2016

ILCA 2016 Annual Conference, Vancouver, Canada, 154. Hepatic catenins, junctions, and cholestasis. Arias Symposia, Boston, MA 11/2016 155. Wnt/Notch/Yap signaling in intrahepatic cholestasis: Implications in Repair 11/2016

cancer. AASLD, Cholestasis SIG annual program, Boston, MA

156. Impaired hepatocyte proliferation triggers biliary/oval cell derived 11/2016 hepatocyte differentiation following hepatobiliary injury. AASLD, Cell Biology SIG annual program, Boston, MA


157. “Modeling Human Liver Cancer in Mice: Biological and Therapeutic 12/2016 Implications," Gastroenterology Grand Rounds, University of Minnesota, Minneapolis, MN

158. “Cellular and Molecular Basis of Hepatobiliary Repair: A Wnt/β-catenin 01/2017 Perspective”, de Duve Institute, Brussels, Belgium

159. “Cellular and Molecular Basis of Hepatobiliary Repair: A Wnt/β-catenin 01/2017 Perspective”, HEPRO meeting, Brussels, Belgium

160. “Modeling Human Hepatocellular Cancer for Precision Medicine”, 02/2017 Tulane University

161. “Modeling Human Liver Cancer in Mice: Biological and Therapeutic 02/2017 Implication”, Cleveland Clinic, Cleveland, OH

162. “Cell Junctions and Barrier: Novel Insights into Cholestatic Liver Disease”, 03/2017 University of Toronto, Toronto, Canada

163. “Coordinated Interactions Between Key Signaling Molecules Lead to Liver 04/2017 Carcinogenesis”, ASIP annual meeting, Experimental Biology, Chicago, IL

164. “Modeling human HCC for precision therapy”, Baylor and Texas A&M 10/2017 Temple, TX

165. “Precision medicine for HCC: A β-catenin perspective”, George 11/2017

Washington University, Washington D.C. 166. “Deciphering pathways of liver regeneration and repair”, School of basic 11/2017

Medical Sciences, Wuhan University, Wuhan, China 167. “Paving the way for personalized medicine in hepatocellular cancer”, 11/2017

Zhongnan Hospital, Wuhan, China 168. “Modeling human HCC in mice: biological and therapeutic implications” 12/2017

Hepatobiliary Cancer: Pathobiology and Translational Advances Conference, Virginia Commonwealth University, Richmond, VA

169. “Molecular pathogenesis of hepatocellular cancer: Paving the way for 02/2018

personalized medicine”, Dayanand Medical College and Hospital, Ludhiana, Punjab, India

170. “Targeting morphogens in cholangiopathies”, Emerging Trends 03/2018 Conference, AASLD, Cholangiopathies: The Dawn of Curative Treatments, Arlington, VA 171. “Viral mechanisms in Primary Liver Cancer”, ASIP Pathobiology Course 04/2018 Infectious Pathogens and Cancer, EB2018, San Diego, CA


172. “β-catenin signaling in hepatobiliary repair”, II Biennial Congress of 06/2018 the European Network for the study of Cholangiocarcinoma

173. “Liver regeneration and repair: A Wnt/β-catenin perspective”, Surrozen 08/2019 San Francisco, CA 174. “Wnt/β-catenin signaling in HCC”. Expert Forum on Gastrointestinal 09/2018 Malignancies, Dallas, TX. 175. “Paving the way for personalized medicine in hepatocellular cancer” 09/2018 University of Illinois, Chicago 176. “Cutting to the chase: Modeling common aberrations in HCC irrespective 09/2018 of etiology and fibrosis”, AASLD Single Topic Conference on Fibrosis, Dallas, TX 177. “Targeting activated myofibroblasts in liver fibrosis”. PISA annual meeting, 10/2018

Molecular Mechanisms of Disease: Tissue Homeostasis, Immune Responses and Cancer, Ann Arbor, MI

178. “Molecular basis of HCC: Paving the way for precision medicine” 10/2018

University of Pittsburgh Cancer Institute, GI Oncology Grand Rounds

179. “Targeting the Wnt/β-catenin pathway in HCC”, NCI, AACR and AASLD 11/2018 joint workshop on HCC, NIH, Bethesda, MD OTHER RESEARCH RELATED ACTIVITIES GRANT REVIEWING: A. National 2019/01 ZDK1 GRB-9 (J2) 1 11/2018 NIDDK Fatty Liver Ancillary Studies NIH ZRG1 IMST-D (02) I Member Conflict 11/2017 Special Emphasis Panel Hepatobiliary Pathophysiology Study Section 06/2017 CSR, NIH Special Emphasis Panel/Scientific Review Group 06/2016 2016/10 ZEB1 OSR-D (O1) S meeting Special Emphasis Panel/Scientific Review Group 03/2016 Member Conflict: Gastrointestinal and Liver Pathobiology and Toxicology 2016/05 Council ZRG1 DKUS-L 04 M Special Emphasis Panel/Scientific Review Group 10/2015 NIH


Special Emphasis Panel/Scientific Review Group 03/2015 NIH Special Emphasis Panel/Scientific Review Group 11/2014 NIH F-2012, GAST VA Merit Study Section Ad-hoc member 2012-2014 Hepatobiliary Pathophysiology (HBPP) Scientific Review group 2008-2013 Charter (Regular) Member, National Institute of Health (NIH) NIH / NIAAA - Special Emphasis Panel ZAA1 JJ (01) – 04/2011 RFA-AA-11-002 R13 Conference Grants Special Emphasis Panel (SEP) Reviewer 03/2009 NCI, NIH Special Emphasis Panel/Scientific Review Group 03/2008 2008/05 ZDK1 GRB-W (M3) meeting, NIH ZDK1 GRB-4 (O1) 1 Review Group 07/2007 NIDDK, NIH, Bethesda, MD ZRG1 DIG-C (02) M Special Emphasis Panel (SEP) 03/2007 NIH Gastrointestinal Cell and Molecular Biology (GCMB) 02/2007 NIH Molecular Oncogenesis. ZRG1 MONC-U (01) (Q) 10/2006 NIH ZRG1 DIG-C (02) M Special Emphasis Panel 06/2006 (CIGP, GCMP, GMPB, HBPP), NIH ZRG1 DIG F (50) Special Emphasis Panel 06/2006 (Bioengineering), NIH Special Emphasis Panel-Reviewer- Beta Cell Biology Consortium (BCBC), 2005 NIDDK, NIH, Bethesda, MD, USA Ad-hoc Reviewer, Hepatobiliary Pathophysiology (HBPP) study section, 2004-2007 NIH B. International French National Research Agency 2011 Blanc Inter II SVSE 1 2011 program


Medical Research Council, UK 2010-2013 Wellcome Trust, London, UK 2010 Concerted Research Actions 2010 2010 University Catholique De Louvain Ontario Ministry of Research, Ontario Research Fund-Research 2009 Excellence Program (ORF-RE) Reviewer for International Union Against Cancer (UICC), 2009- UICC International Cancer Technology Transfer (ICRETT) fellowships Geneva, Switzerland French National Cancer Institute 2009 Institut National du Cancer - INCa Science Operations and Funding Directorate 06/2008 Cancer Research UK Biotechnology and biological sciences research council (BBSRC), 03/2007 United Kingdom Technology Foundation STW - Dutch funding agency financed by 2005 Netherlands Organisation for Scientific Research, NOW & Dutch Ministry Peer review as an external reviewer for the Department of Experimental 2004 Oncology CRO-IRCCS, Aviano National Cancer Institute, Aviano, Italy. University Grants Committee, Research Grants Council of Hong Kong, 2003, 2012 Hong Kong, China C. Private AASLD and ALF Joint Research Awards Committee 2011-2015 ALF Grant Review Committee 2010-2011 Science & Technology Development Program 08/2007 North Carolina Biotechnology Center JOURNAL REFEREEING: Editor-in-Chief: – Current Pathobiology Reports (New Springer Journal) 2011-2016 Online quarterly review journal – Gene Expression: The Journal of Liver Research 2015-present Associate Editor – Seminars in Liver Diseases 2016-present


– Journal of Hepatology 2014-2016 – American Journal of Pathology 2008-present – BMC Cancer 2009-2014 Editorial Committee – Annual Reviews of Pathology: Mechanisms of Disease 2014-present Section Editor – Archives of Pathology and Laboratory Medicine (Molecular Pathology) 2008-present Guest Editor: – Organogenesis Apr-Jun: 2008 Editorial Board Member: – JCI Insights Jan. 2016- – Journal of Hepatology July 2012- – Gastroenterology July 2011- – World Journal of Gastrointestinal Pathophysiology Jan. 2011- – American Journal of Physiology: GI and Liver Physiology Sep. 2009- – Hepatology Jan. 2009- – Organogenesis Mar. 2008- – World Journal of Gastroenterology Jan. 2006- – Archives of Pathology and Laboratory Medicine Jul. 2008- – The Open Hepatology Journal Jan. 2009- – Hepatology International Jan. 2010- TEXTBOOK EDITOR: – Molecular Pathology of Liver Diseases Dec. 2010 Editor: Satdarshan P.S. Monga Molecular Pathology Library, Springer publishers SECTION EDITOR OF ONLINE RESOURCE/TEXTBOOK: Encyclopedia of Pathology and Human Disease Jan. 2011 Section: Hepatobiliary Pathobiology: Cellular & Molecular Mechanisms Editors: Linda MacManus and Richard Mitchell Ad hoc referee: – Science – Nature Medicine – Cancer Cell – PNAS – Nature Communications – Journal of Clinical Investigation – Genes and Development – Development – Current Biology – American Journal of Physiology-GI and Liver Physiology – Gastroenterology – Hepatology – American Journal of Pathology – Gut


– Stem Cells – Stem Cells and Development – Cell Transplantation – Genes, Chromosomes and Cancer – Cancer Letters – Expert Opinions in Biological Therapy – Carcinogenesis – Journal of Hepatology – Gynecologic and Obstetric Investigation – Neoplasia – Digestive Diseases and Sciences – Liver International – Journal of Histochemistry and Cytochemistry – Journal of Pathology – Digestive Diseases Science – Expert opinion on biological therapy – Clinical Cancer Research – World Journal of Gastroenterology – FEBS Letters – Human Pathology – Wound Repair and Regeneration – Toxicological Sciences Lists of Current Research Interests Wnt signal transduction pathway Personalized Medicine Signaling pathways (HGF/PDGF/NF-κB/EGF/Others) Liver Growth and Development Liver Cancer Liver Stem Cells Liver Regeneration Cell transplantation Cancer stem cells Bioreactor Technologies Alcoholic Liver disease Nonalcoholic Fatty Liver disease (NAFLD and NASH) Pathogenesis of Hepatic Fibrosis Bile duct development and Biliary differentiation Hepatocyte Differentiation Cholangiopathies Acute liver failure


SERVICE INTERNATIONAL Virtual Liver Network, Heidelberg, Germany 2011-2015 Scientific Advisory Board Program Chair, Joint ASIP and 2008-2014 Congress of Italian Society of Pathologists Technical Program Committee Member 2010-2011 Annual International Conference on Stem Cell Research NATIONAL Currents Trends in Stem Cell Therapies, NIH T32 2018-present External Advisory Board University of Louisville, Kentucky NIH-funded P20 Hepatobiology and Toxicology COBRE 2017-present External Advisory Committee University of Louisville, Kentucky Program Chair 2017 American Society of Investigative Pathology Standalone Meeting Secretary Treasurer 2016-present American Society of Investigative Pathology Program Chair -Elect 2014-2016 American Society of Investigative Pathology Chair, Abstract Review Committee 2010-2015 Experimental Hepatobiliary Neoplasia AASLD and DDW Chair, Special Task Force on Meetings and Courses 2010-2015 American Society of Investigative Pathology Chair, Liver Interest Group 2009-present American Society of Investigative Pathology Liver Center External Advisory Committee 2009-present Albert Einstein, College of Medicine, Yeshiva University Elected Organizer, FASEB summer research conference on 2008-present “Liver growth Development and Disease” Member-Basic Research Committee 2009-2011 AASLD


Program Chair 2008-2010 American Society of Investigative Pathology Long Range Planning Committee 2006-2008 American Society of Investigative Pathology Program Committee Member for the American Society of Investigative 2003-2008 Pathology, (FASEB, Experimental Biology: 2005-2006) PHARMACEUTICAL Dicerna Pharmaceuticals 2016-2017 Fibrosis Advisory Board Abbvie 2014-2017 Liver Advisory Board Merck 2012-2013 Consultant, HCC SIE Phase-Rx 2012-2013 Consultant, Liver Cancer Treatment Bristol Myers Squibb 2012-2013 Consultant, Liver Fibrosis Scientific Advisory Board ImClone Therapeutics 2008-2012 New Jersey, NJ UNIVERSITY OF PITTSBURGH AND UNIVERSITY OF PITTSBURGH MEDICAL CENTER Director, Pittsburgh Liver Research Center 2016-present SCHOOL OF MEDICINE

Member, Transgenic Advisory Committee 2007-2013 University of Pittsburgh, SOM Member, UPSOM Admissions Interviewing Committee 2015-2016 University of Pittsburgh, SOM GRADUATE PROGRAM (IBGP) Member-Admissions Committee, Indian subcommittee, 2004-2016 Interdisciplinary Biomedical Graduate Program Member-Recruiting Committee, Graduate program in 2004-2015 Interdisciplinary Biomedical Graduate Program Steering Committee Member, Cellular Molecular Pathology 2005-Present Graduate Program, IBGP, University of Pittsburgh, SOM


DEPARTMENT OF PATHOLOGY Menten Lecture Committee 2013-Present Vice Chair and Division Chief: Division of Experimental Pathology 2009-Present

Department of Pathology Department Tenure Committee 2012-Present Junior Faculty Steering Committees, 2010-Present Division of Experimental Pathology Member-Annual Pathology Retreat Organization Committee 2005-Present Department of Pathology Steering Committee Member 2001-Present Pathology Postdoctoral Research Training Program (PPRTP) Judge, Annual Pathology Retreat 2001-Present Annual Research Day, Department of Pathology DEPARTMENT OF MEDICINE Chair, Search Committee for Division Chief of Gastroenterology, 2016-2017 Hepatology and Nutrition Member-GI Fellowship Interview Committee 2009-2014 Division of Gastroenterology, Hepatology and Nutrition Department of Medicine, UPMC UNIVERSITY OF PITTSBURGH CANCER INSTITUTE (UPCI) Member, Molecular and Cellular Biology Program 2002-Present UPCI Organizer- Cancer Stem Cell Workshop, 2007 University of Pittsburgh Cancer Institute Annual Retreat McGOWAN INSTITUTE OF REGENERATIVE MEDICINE (MIRM) Program Director 2012-Present Cell and Tissue Engineering Approaches to Regeneration T32, Predoctoral Graduate Training Program, MIRM Member, Liver Interest Group 2001-Present MIRM Member-Trainee Admission and Evaluation Committee, 2003-Present Cellular Approaches to Tissue Engineering/Regeneration (NIH, T32)


Director, MIRM Trainee Career Advancement Program 2005-Present University of Pittsburgh, SOM Member-Institute Search Committee for McGowan Institute of 2003-2005 Regenerative Medicine Director, McGowan Institute (of Regenerative Medicine) Graduate 2002-2005 Students Network, (MIGS-Net) Team Leader, Cellular Approaches to Tissue Engineering/Regeneration 2003 (CATER) section at the annual MIRM retreat

Documents

Satdarshan P. Singh Monga CURRICULUM VITAE …...Ko S, Russell JO, Tian J, Gao C, Kobayashi M, Feng R, Yuan X, Shao C, Ding H, Poddar M, Singh S, Locker J, Weng HL, Monga SP, Shin